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Abstract: With no currently available disease-modifying drugs, Alzheimer’s disease is the most common 
type of dementia affecting over 47 million people worldwide. In light of the most recent discoveries placing 
the cellular prion protein (PrPC) as a key player in amyloid β oligomer (Aβo)-induced neurodegeneration, 
we investigated whether the neuroprotective potential of nature-inspired flavonoids against Aβ-promoted 
toxicity would translate into the ability to disrupt PrPC-Aβo interactions. Hence, we synthesized a small 
library of flavones and studied their binding affinity towards Aβo by STD-NMR. C-glucosyl flavones exhib-
ited improved binding affinity with morpholine, thiomorpholine or N-methylpiperazine rings attached to the 
flavone skeleton in ring B para position. Moreover, a N-methylpiperazinyl flavone displayed suitable physico-
chemical properties and optimal water solubility even without the sugar moiety, and a high interaction with 
Aβo involving the whole flavone core. Its C-glucosyl derivative, was, however, the best compound to inhibit 
PrPC-Aβo interactions in a dose-dependent manner, with 41 % of inhibition capacity at 10 µM. The potential 
of C-glucosyl flavones and their aglycones as protein-protein interaction inhibitors able to tackle PrPC-Aβo 
interactions is here presented for the first time, and supports this class of compounds as new prototypes for 
further development in the treatment of Alzheimer’s disease.
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Introduction
Alzheimer’s disease (AD) is the most common form of dementia, presently affecting more than 47 million 
people globally [1]. Symptoms include memory and judgement impairment, disorientation, confusion, mood 
swings, among others, and their management is associated with a heavy emotional and financial burden 
to patients, families and national health care systems [2]. With the increase in life expectancy and higher 
incidence of type 2 diabetes (T2D), which is nowadays generally accepted as a major risk factor for dementia, 
the number of AD patients is estimated to rise to more than 131 million by 2050 [1, 3]. In spite of these projec-
tions, cholinesterase inhibitors including the highly prescribed donepezil, rivastigmine and galantamine, are 
some of the very few drugs currently available for treating AD. What’s more, in addition to a poor risk-benefit 
relationship [4], these drugs are not supported by robust evidence indicating disease-modifying effects, thus 
placing the pursuit for new molecular entities able to interfere with the progression of AD as one of the 
highest priorities of health care providers worldwide.
Since 1992, the amyloid cascade hypothesis has been at the heart of the vast majority of publications 
concerning the pathophysiology and treatment of AD. Originally postulated by Hardy and Higgins, this 
hypothesis posits that the accumulation of amyloid β (Aβ) in the brain is responsible for the formation of 
neurofibrillary tangles, as well as the increase in intraneuronal calcium (Ca2+) concentrations that ultimately 
result in neuronal death [4, 5]. Even though the initial focus of most AD scientists was on the dense Aβ fibril 
networks that constitute amyloid plaques, the past decade has led the scientific community to agree that 
much smaller Aβ oligomers (Aβo) are actually the most neurotoxic amyloid species of Aβ. With a spherical 
shape ranging from 3 nm up to 10 nm in size [6], soluble Aβo appear to affect dielectric properties of cell 
membrane by bilayer insertion and domain formation, and to disrupt neuronal membrane trafficking [7, 8]. 
More recently, however, new evidence on the role of the cellular prion protein (PrPC) in the molecular mecha-
nisms underpinning the detrimental effects of Aβo in AD started to emerge. In 2009, Laurén and co-workers 
described PrPC as a high affinity cell-surface receptor for soluble Aβo, being able to mediate synaptic impair-
ment caused by Aβo [9]. Accordingly, Prnp(−/−) mice (genetically engineered prion protein-deficient mice) are 
resistant to the neurotoxic effects of Aβo in vivo and in vitro [10]. With the subsequent discovery of Fyn kinase 
as a key mediator in Aβo-PrPC-induced neuronal damage [11], it is currently believed that the Aβo-PrPC inter-
action triggers metabotropic glutamate receptor-5 (mGluR5)-dependent signalling events leading to the acti-
vation of Fyn kinase, with ensuing NMDA-mediated intracellular Ca2+ influx, and activation of kinases such 
as glycogen synthase kinase 3β (GSK-3β) and protein tyrosine kinase 2 (Pyk2), which are ultimately involved 
in tau hyperphosphorylation [12, 13]. These data strongly suggest that tackling Aβo-PrPC interactions with 
effective protein-protein interaction inhibitors (PPIIs) might lead to new therapeutic approaches against AD 
progression.
Chicago sky blue, a dye used in fluorescence and immunofluorescence histochemistry, is so far the only 
small molecule shown to disrupt the binding between Aβ and PrPC [14]. Given the potential of Aβo-PrPC as a 
therapeutic target in AD, we believe that it is imperative to find new lead scaffolds with the ability to tackle 
the interaction between both partners, and to investigate whether molecules known to have binding affinity 
towards Aβ and/or exert neuroprotective effects could, in fact, act by disrupting Aβo-PrPC interactions. In 
this perspective, we followed a line of investigation that started with the recognition of chrysin (Fig. 1a) as a 
suitable prototype structure for the interaction with Aβ and inhibition of small Aβo formation [15]. We were 
furthermore interested in finding out if the insertion of a C-glucosyl moiety could somehow optimize the 
activity of chrysin derivatives, since vitexin (Fig. 1a) and other glycosyl flavones had been described to exert 
neuroprotective effects against Aβ-induced toxicity in vitro [16, 17]. Hence, we directed our research efforts to 
the design and synthesis of a primary series of flavones and corresponding C-glucosyl derivatives, from which 
our preliminary screening tests selected both morpholinyl derivatives 1 and 2 (Fig. 1b) as the most promis-
ing neuroprotective agents against Aβ
1-42
-induced toxicity in SHSY-5Y human neuroblastoma cells, with the 
ability to restore cell viability at 50 µM (unpublished data).
The present work focuses on the chemical modifications introduced in the lead compounds 1 and 2 
that resulted in the discovery of new molecules able to disrupt Aβo-PrPC interactions. Figure 2 summarizes 
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our strategy for the design and synthesis of a small library of C-glucosyl flavone derivatives and their corre-
sponding aglycones, which included a series of bioisosteric replacements of ring D, as well as the insertion 
of halogen atoms in ring B, among other alterations. Our main goal was to explore the potential of these 
compounds by STD NMR in order to evaluate their binding affinity towards Aβo, while developing a brief 
Fig. 1: (a) Chemical structure of chrysin and vitexin, two natural products with the ability to interact with Aβ; (b) lead scaffolds 
for the present study, compounds 1 and 2.
Fig. 2: Strategy for chemical modifications towards the optimization of the lead scaffold.
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structure-activity relationship study. We subsequently present a functional assay aimed at exploring if some 
of the most relevant interactions with Aβo could translate into the highest potential to disrupt Aβo-PrPC 
interactions.
Chemistry
The synthetic route for C-glucosyl flavone derivatives started with a TMSOTf-promoted reaction between gly-
cosyl donor 3 and 2,4,6-trihydroxyacetophenone 4, to give intermediate 5 (Scheme 1). Then, after selective 
benzylation of two hydroxy groups, chalcone intermediates 7–20 were generated in base-catalysed Claisen-
Schmidt aldol condensation reactions under high temperature of compound 6 with different aldehydes. In 
order to engage in an efficient and highly systematized synthetic process, only commercially available alde-
hydes or their N-Boc protected derivatives were chosen to be used in this step. Lastly, the chalcones were 
cyclized in the presence of iodine and pyridine, after which all protecting groups were removed using BBr
3
 at 
−78 °C to give the final compounds 1 and 21–32.
As for the non-glycosylated flavones, 2,4,6-trihydroxyacetophenone (4) was selectively protected with 
ethoxymethyl ether groups (EOM) in a K
2
CO
3
-promoted reaction to afford compound 33 (Scheme 2). Then, in 
the presence of each aldehyde, chalcone intermediates 34–46 were generated following the same procedure 
described for the synthesis of C-glucosyl chalcones; however due to the use of smaller protecting groups 
and absence of the sugar moiety, these reactions proceeded efficiently at room temperature. Finally, each 
chalcone went through the oxidative cyclization reaction in the presence of iodine and pyridine, followed by 
deprotection using catalytic amounts of p-toluenesulfonic acid (p-TSOH) and acetic acid (AcOH) in ethanol 
under reflux, to give the final compounds 2 and 47–57.
Notably, compounds 14 and 46 bearing the morpholine group in ortho position of ring B, did not afford 
the corresponding flavones due to chemical instability of the protected intermediates and/or the final com-
pound. Reaction yields of all compounds are provided in Table 1. C-Glucosyl chrysin 21 was also synthesized 
for comparison purposes.
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Scheme 1: Synthesis of C-glycosyl flavones. Reagents and conditions: (a) ACN/DCM, drierite, TMSOTf, −40 °C → r.t., 18 h, 57 %; 
(b) DMF, K
2
CO
3
, BnBr, 0 °C → r.t., 4 h, 64 %, (c) aldehyde, aq. NaOH 50% (w/v), 1,4-dioxane, 92 °C, 18 h–24 h, 38%–76%; (d) (1) 
I
2
, pyridine, reflux, 48 h–72 h; then, (2) BBr
3
, DCM, −78 °C, 2 h–4 h, 24 %–95 % over two steps.
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Molecular interaction studies and structure-activity relationships
All synthesized compounds were tested for their affinity towards Aβo in a screening STD NMR, an assay pre-
viously adopted for the study of other polyphenol interactions with Aβo [18]. Oligomers were freshly prepared 
and their size confirmed by dynamic light scattering (DLS), with the vast majority of the amyloid aggregates 
exhibiting radii between 1 nm and 10 nm (see Supporting Information, Fig. S1). Bexarotene, a high-affinity 
Aβ
1-42
 ligand with proven ability to block primary and secondary nucleation events in the amyloid aggregation 
pathway [19], was used in this study as positive control. As negative control, we used 2 % DMSO (Fig. S2) – the 
same DMSO percentage used as vehicle in each assay. Figure 3 presents STD NMR results for the C-glucosyl 
flavones that exhibited any detectable interaction with Aβo.
When looking into the difference spectrum of lead compound 1, STD signals corresponding to protons 
H-3 and H-6 of the flavone core can be observed at 6.53 ppm and 6.13 ppm, respectively. When compared to 
C-glucosyl chrysin 21, which displays signals corresponding to H-3 (6.71 ppm) and aromatic protons H-2′ and 
H-6′ (7.56 ppm), but not H-6, the results suggest that the morpholine moiety in compound 1 is able to change 
the binding mode of these types of compounds towards Aβo, by inducing the participation of ring A in the 
interaction between the flavone and the target protein aggregates.
From all the data presented in Fig. 3, the group of spectra referring to compound 22 stands out for the 
STD NMR signals corresponding not only to all olefinic and aromatic protons in the flavone core, but also to 
the anomeric proton H-1″, at 4.89 ppm. This indicates that, on the one hand, the bioisosteric replacement of 
the endocyclic oxygen with a sulfur atom in the morpholine moiety increases the binding affinity between the 
flavone skeleton and the target protein by promoting an interaction involving all the protons of the flavone 
skeleton. On the other hand, this replacement additionally leads to the involvement of the sugar moiety in 
the established contact. Conversely, the bioisosteric replacement of the morpholine with a piperidine group 
in compound 23 causes a significant loss in binding affinity. In this case, only the STD signal correspond-
ing to the olefinic proton H-3 is unequivocally detected, while the remaining interactions have a very low 
and irrelevant signal-to-noise ratio. This result points to the presence of a heteroatom in the terminal end 
of the morpholine group as a definite structural requirement for the induction of optimal binding affinity 
of the C-glucosyl flavone scaffold towards Aβo. The lack of observable STD interactions detected for both 
the N,N-dimethyl 31 and the N-N-biphenyl 32 derivatives further corroborates this hypothesis. Moreover, the 
same lack of detectable STD signals in the case of the ortho-morpholinyl derivative 30 highlights the need for 
ring D to be in para position of ring B in these C-glycosyl flavones.
While the N-methylpiperazine in compound 25 still retains some level of interaction with the target protein 
aggregates, the piperazine group in its analogue 24 completely abolished any observable STD signals (data 
not shown). However, the N-methylpiperazinyl C-glucosyl flavone 26 containing an additional CH
2
  bridge 
HO OH
OH O
a EOMO OH
EOMO O
b EOMO OH
EOMO O
R
c HO O
HO O
R
4 33 34–46
2, 47–57
Scheme 2: Synthesis of non-glycosylated flavones. Reagents and conditions: (a) K
2
CO
3
, acetone, EOMCl, reflux, 4 h, 91 %*; 
(b) aldehyde, aq. NaOH 50 % (w/v), 1,4-dioxane, r.t., 3 h–24 h, 62 %–99 %*; (c) (1) I
2
, pyridine, reflux, 24 h–72 h; then,  
(2) p-TsOH in AcOH, EtOH, reflux, 2 h–24 h, 63 %–99 %* over two steps. *Reaction yields determined by LCMS.
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Table 1: Reaction yields of chalcone intermediates and final flavones.
R  
 
 
Yield
C-glucosyl flavones     Non-glucosylated flavones
Aldol condensationa   Cyclization and 
deprotectionb
Aldol condensationb   Cyclization and 
deprotectionb
  (7) 44 %   (21) 88 %   n.a.c   n.a.c
  (8) 67 %   (1) 74 %   (34) 76 %   (2) 99 %
  (9) 68 %   (22) 24 %   (35) 77 %   (47) 99 %
  (10) 56 %   (23) 92 %   (36) 75 %   (48) 65 %
  (11) 71 %
[R=Boc]
  (24) 77 %
[R=H]
  (37) 62 %
[R=Boc]
  (49) 99 %
[R=H]
  (12) 63 %   (25) 70 %   (38) 83 %   (50) 79 %
  (13) 58 %   (26) 84 %   (39) 99 %   (51) 90 %
  (14) 61 %   (27) 90 %   (40) 73 %   (52) 92 %
  (15) 76 %   (28) 76 %   (41) 76 %   (53) 93 %
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between rings B and D succeeded at further recovering interaction points with Aβo in both rings A and B, 
with STD-NMR signals corresponding to protons H-3 and H-6 being unambiguously detected in the difference 
spectrum, at 6.70 ppm and 6.11 ppm, respectively.
From all the halogen-containing C-glucosyl flavone derivatives, compound 29 was the only analogue pre-
senting a satisfactory binding interaction with Aβo by STD NMR. STD signals matching protons H-6′ and H-3′ 
in ring B, as well as protons H-3 and H-6 in rings C and A, respectively, are clearly visible. We propose that the 
difference in bulkiness between the halogens in compounds 28 and 29 might be the underpinning reason for 
this result, as the larger size of the bromine atom might trigger alterations in the conformation and/or spatial 
orientation of the morpholine moiety, leading to a more suitable overall conformation of the flavone core. Yet, 
the introduction of the halogen did not match the full effect of the thiomorpholinyl detivative 22, as the STD 
NMR signal for the anomeric proton H-1″ failed to be observed in its difference spectrum.
Contrarily to the C-glucosyl flavones, aglycones generally displayed relevant water solubility issues. For 
this reason, the solvent pH had to be increased until signal-to-noise ratio was satisfactory in the reference 
spectra. However, none of the aglycones succeeded in presenting any signs of interaction with Aβo by STD 
NMR, with the exception of compound 51 (Fig. 4).
R  
 
 
Yield
C-glucosyl flavones     Non-glucosylated flavones
Aldol condensationa   Cyclization and 
deprotectionb
Aldol condensationb   Cyclization and 
deprotectionb
  (16) 76 %   (29) 95 %   (42) 77 %   (54) 84 %
  (17) 40 %   (30) 55 %   (43) 81 %   (55) 85 %
  (18) 55 %   n.d.d   (44) 84 %   n.d.d
  (19) 55 %   (31) 91 %   (45) 99 %   (56) 96 %
  (20) 74 %   (32) 85 %   (46) 61 %   (57) 63 %
aIsolated yield; breaction yields determined by LCMS; cnot applicable; dnot detected.
Table 1 (continued)
Authenticated | aprauter@fc.ul.pt author's copy
Download Date | 8/24/19 12:24 PM
1114      A. M. Matos et al.: Discovery of N-methylpiperazinyl flavones
The design of both compounds 26 and 51 was based on the introduction of a CH
2
 bridge between rings 
B and D to increase molecular flexibility by allowing ring D to rotate around the new C–N bond. Indeed, 
compound 51 (Fig. 4b) was the only one amongst the synthesized set of aglycones to present good water 
solubility, despite the highly lipophilic flavone core. It was also the only aglycone presenting any STD inter-
actions with Aβo and, overall, one of the most promising molecules of this study. Figure 4a shows that the 
binding mode of compound 51 towards Aβo unequivocally involves both aromatic protons of ring A (H-6 
and H-8, at 6.10 ppm and 6.37 ppm), all aromatic protons of ring B (H-2′, H-3′, H-5′ and H-6′, at 7.45 ppm and 
7.91 ppm), as well as the olefinic proton in ring C, H-3 (at 6.63 ppm). With a much lower signal-to-noise ratio, 
small peaks that could correspond to the protons of the piperazine moiety appear at 2.16 ppm and 1.85 ppm; 
however, due to the background spectrum (see Supporting Information, Fig. S2), it is not possible to cor-
rectly assign the exact origin of these signals. All in all, the comparison between the signal-to-noise (SNR) 
relative intensity of the binding epitope points towards H-3 as the most relevant point of interaction between 
compound 51 and the target amyloid aggregates, followed by both protons in ring A, H-6 and H-8 (Fig. 4c). 
Although significant, the interaction between ring B and Aβo does not appear to contribute as much to the 
binding epitope of this molecule.
The Central Nervous System (CNS)-MultiParameter Optimization (MPO) algorithm is a published math-
ematical tool that enables the alignment of six key drug-like attributes (partition coefficient, distribution 
coefficient, pKa, molecular weight, topological polar surface area and the number of hydrogen bond donors), 
by providing an estimation of a given small molecule to enter the central nervous system, while displaying 
Fig. 3: STD-NMR screening assays to assess the binding affinity of flavones against Aβo. For reference (REF) and difference 
(DIFF) spectra, compounds were added in DMSO to a 2 µM solution of freshly prepared Aβo in a mixture of deutered phosphate 
buffer (pH 7.4) and neurobasal medium, to achieve a final compound concentration of 200 µM (1:100 molar ratio). Control (CTRL) 
experiments were carried out in the same conditions, but in the absence of Aβo.
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favourable permeability, P-gp efflux, metabolic stability and safety [20]. From a scale of 0–6, compound 51 
exhibited a CNS-MPO desirability score of 4.9, which is highly preferable to the 2.5–3.6 scores exhibited by 
C-glucosyl flavones, at least in view of mere passive diffusion processes. Based on these data, and given 
that compound 51 was the only water soluble aglycone in this study with proven ability to bind to the target 
amyloid aggregates, we decided to further explore the potential of our N-methylpiperazinyl flavones in this 
study, particularly focusing on compound 51.
We thus conducted an STD NMR competition experiment between analogue 51 and the high-affinity Aβ 
ligand bexarotene, in order to assess if any of these two compounds could act as an enhancer or inhibitor 
of each other’s binding affinity towards Aβo. Moreover, based on some level of structure similarity between 
them, we were also interested in investigating whether they would bind to the same or different binding 
sites in the target protein. Figure 5 shows that bexarotene displaced compound 51 from binding to Aβo, with 
only a very small STD signal corresponding to H-6 of 51 appearing in the difference spectrum. While these 
data indicate that bexarotene ought to have a higher binding affinity towards the target, they also show that 
 compound 51 possibly interacts with Aβo at the same binding site as bexarotene. This compound binds to a 
linear motif at the C-terminal of Aβ
1-42
 peptide, in a region encompassing residues 22–35, being therefore able 
not only to inhibit cholesterol-induced oligomerization of Aβ
1-42
 into calcium-permeable ion channels formed 
by Aβ
1-42
 in the neuronal lipid membrane, but also to counteract the disruption of actin cytoskeleton induced 
by Aβo [21, 22]. If 51 and bexarotene are both able to bind to the same binding site(s) in Aβo, it is plausible 
that 51 and structurally-related compounds might also have an impact in these mechanisms that contribute 
to the neurodegenerative process in AD.
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Fig. 4: Binding affinity of flavone 51 against Aβo, assessed by STD-NMR. (a) STD-NMR results: for the reference (REF) and 
difference (DIFF) spectra, 51 was added in DMSO to a 2 µM solution of freshly prepared Aβo in a mixture of deutered phosphate 
buffer (pH 7.4) and neurobasal medium, to achieve a final compound concentration of 200 µM (1:100 molar ratio); the control 
(CTRL) experiment was carried out in the same conditions, but in the absence of Aβo; (b) chemical structure of flavone 51; 
(c) SNR relative intensity for STD-NMR signals of protons H-3, H-6, H-8 and aromatic protons of flavone 51; results are presented 
in percentages, calculated using MestReNova SNR script tool; for each STD signal, relative intensities were calculated by 
dividing the corrected SNR on the difference spectrum by the corresponding SNR on the reference spectrum.
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Assessment of Aβo-PrPC interaction disruption by flavones
The next step in this investigation was to assess if the STD NMR results obtained for compound 51 and related 
N-methylpiperazinyl flavones could translate into a positive outcome in a functional assay. Hence, we tested 
this small set of molecules on their ability to disrupt Aβo-PrPC interactions in human embryonic kidney (HEK) 
cells, in which PrPC is endogenously expressed.
From all tested compounds, C-glucosyl flavone analogue 26 exhibited the highest potential do disrupt 
Aβo-PrPC interactions (Fig. 6a), presenting an inhibition percentage of 41 % at 10 µM, with high statistical 
significance when compared to Aβo-PrPC control (P-value < 0.001). As displayed in Fig. 6a, this compound 
shows a significantly better prognosis for further development when compared to its aglycone, compound 51: 
in fact, contrarily to our initial expectation, the higher number of interaction points with Aβo in the STD NMR 
screening experiment did not necessarily translate into the highest interaction-disrupting potential (a similar 
result was obtained for the bromine-containing C-glucosyl derivative 29, with just 26 % of Aβo-PrPC binding 
inhibition percentage; see Supporting Information, Fig. S3). These results seem to indicate: (1) that compound 
51 has greater binding affinity for Aβo in a region that is not involved in Aβo-PrPC interaction; and (2) that 
compounds 26 and 50, which displayed only moderate or low affinity towards Aβo by STD NMR, are none-
theless able to bind to the Aβo-PrPC interaction surface, thus competing with Aβo for binding towards PrPC. 
Moreover, in the case of the pair of compounds 26/51, the sugar moiety was clearly able to tune the activity of 
the aglycone towards a more specific interaction between the compound and the complex Aβo-PrPC. What’s 
more, Fig. 6b shows that the effect of 26 is dose-dependent, with statistical significance achieved from 10 µM 
to 20 µM of compound when compared to the Aβo-PrPC control.
Fig. 5: STD-NMR competition assay between compound 51 and bexarotene towards Aβo. (a) Mixture between compound 51 and 
bexarotene, both at 200 µM; (b) compound 51 at 200 µM; (c) bexarotene at 200 µM. For reference (REF) and difference (DIFF) 
spectra, compounds were added in DMSO to a 2 µM solution of freshly prepared Aβo in a mixture of deutered phosphate buffer 
(pH 7.4) and neurobasal medium. Control (CTRL, CTRL REF or CTRL DIFF) experiments were carried out in the same conditions, 
with 4 % DMSO, but in the absence of Aβo.
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In a MTT assay performed in the same cell line, none of the four N-methylpiperazinyl flavones exhibited 
relevant signs of cytotoxicity at 20 µM, with average cell survival rates above 77 % in all cases. However, cells 
treated with 50 µM of aglycones 50 and 51 only displayed 56 % ± 3 % and 36 % ± 6 % of cell viability, respec-
tively, whereas their C-glycosides displayed 91 % ± 4 % and 79 % ± 1 %, in turn. These results indicate that 
C-glycosylation could be viewed as a valuable tool for reducing the cytotoxicity of flavones as well. Anyhow, all 
four N-methylpiperazinyl flavone derivatives 25–26 and 50–51 presented statistically significant differences in 
the number of Aβo-PrPC units when compared to the non-treated control (Fig. 6a) and, thus, the use of these 
types of compounds as blockers of Aβo-PrPC interactions should ultimately be regarded as a novel strategy 
against neuronal damage in Alzheimer’s disease, with potential for further development and optimization.
Conclusions
In this work, we presented the synthesis of 24 novel C-glucosyl flavones and aglycones with therapeutic 
potential against AD. Based on the existing robust evidence pointing towards Aβo-PrPC complexes as valu-
able therapeutic targets for the development of PPIIs with neuroprotective activity, our goal was to study the 
synthesized compounds as Aβo-binders, and to assess whether the best molecules would also behave as 
promising Aβo-PrPC interaction blockers.
C-glucosyl derivatives displayed optimal water solubility and were generally able to interact with Aβo by 
STD NMR. On the other hand, compound 51 stood out from the set of non-glycosylated derivatives for being 
the only water-soluble aglycone, and the only one to exhibit the ability to interact with the target amyloid 
aggregates. Indeed, the presence of the (4-methylpiperazin-1-yl)methyl moiety in this flavone derivative 
results in higher molecular flexibility when compared to its planar analogues, and allows free rotation of the 
 N- methylpiperazinyl group around ring B without compromising brain penetrance estimations by passive 
diffusion. Ultimately, this feature successfully promoted the establishment of interactions between com-
pound 51 and Aβo mediated by the whole flavone core. Our results additionally indicate that compound 51 
competes with the bexarotene for the same binding site(s) in Aβo. To this point, mostly due to the low sta-
bility and high size variability of Aβo, it is not clear exactly where bexarotene binds in these small amyloid 
aggregates; nevertheless, our data suggest that compound 51 and related analogues might have the potential 
to yield similar effects by interfering with damaging events directly induced by Aβo, such as the disruption of 
the actin cytoskeleton in neurons [21].
A cell-based functional assay in HEK cells revealed that all four N-methylpiperazinyl flavone derivatives 
were able to significantly disrupt the binding between Aβo and PrPC at 10 µM. Compound 26, the C-glucosyl 
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Fig. 6: Ability of N-methylpiperazinyl flavones to disrupt binding interactions between Aβo-PrPC in HEK cells. (a) screening 
assay with C-glycosides and their aglycones at 10 µM; (b) dose-response effects of compound 26. Results are presented as 
means ± standard deviation of two experiments preformed in triplicates. Statistical differences between groups were assessed 
by one-way ANOVA followed by a Tukey’s post-test. *P < 0.05, **P < 0.01 and ***P < 0.001 vs. Aβo-PrPC control; §P < 0.05 vs. 
another compound.
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derivative of 51, presented the highest ability to block Aβo-PrPC interactions in a dose-dependent manner, 
with 41 % of inhibition capacity at 10 µM. Interestingly, significant differences were observed when com-
paring its activity to that of its aglycone, indicating that, in this particular case, the sugar moiety was able 
to optimize the affinity of aglycone 51 towards the Aβo-PrPC interaction region, possibly being itself part of 
the binding epitope. Even though sugars are not the best candidate scaffolds for crossing the blood-brain 
barrier by passive diffusion due to their physicochemical properties, previous evidence has recognized sugar 
conjugates as molecules with adequate brain-penetrating capacity (in some cases improved when compared 
to their aglycones) [23, 24]. In fact, it is thought that the sugar moiety might behave as a shuttle and induce 
the passage of the compound into the CNS due to its high affinity towards glucose transporter 1 (GLUT-1) 
located in the blood-brain barrier (BBB), even though the transport can occur in both directions (in and out 
of the brain). Examples include the C-glucosyl flavone spinosin, and anthocyanin glycosides, among others 
[25–27]. Ultimately, we show, for the first time in this work, the potential of non-toxic N-methylpiperazinyl 
flavones and their sugar conjugates as Aβo-PrPC interaction disruptors, thus opening a new line of investiga-
tion towards the discovery of new drug candidates with neuroprotective potential against AD progression.
Experimental section
Chemistry
HPLC grade solvents and reagents were obtained from commercial suppliers and were used without further 
purification. Chrysin was purchased from Sigma Aldrich. LCMS experiments were performed in a column 
XBridge C18 3.5u 2.1 × 50 mm at 1.2 mL/min and 50 °C; 10 mM ammonium bicarbonate pH 9/ACN, gradient 
10 > 95 % ACN in 1.5 min + 0.5 min hold. Flash column chromatography was performed using CombiFlash® 
Rf200 (Teledyne Isco). Preparative HPLC was performed in a Gilson apparatus using either Phenomenex 
gemini NX, C18, 5 µm 30 × 100  mm or Phenomenex gemini NX, C18, 10 µm 50 × 150  mm columns. NMR 
spectra for compound characterization were recorded on a Bruker AV III HD Nanobay spectrometer running 
at 400.13  MHz equipped with a room temperature 5  mm BBO Smartprobe with Z-gradients capable of 19F 
observation. Chemical shifts are expressed in δ (ppm) and the proton coupling constants J in hertz (Hz). 
NMR data were assigned using appropriate COSY, DEPT, HMQC, and HMBC spectra. For the characterization 
of chalcones, protons and carbons in ring A (aromatic ring attached to the carbonyl group) are assigned as 
H′, C′; in ring B (aromatic ring attached to the propenone double bond) as H″, C″; and those belonging to 
the glucosyl moiety as H‴, C‴, while propanone atoms are labeled from 1 to 3, to facilitate the description 
of compound chemical shifts. Melting points were measured with a SMP3 melting point apparatus, Stuart 
Scientific, Bibby Melting points were obtained with a SMP3 Melting Point Apparatus, Stuart Scientific, Bibby 
(r.t. < m.p. < 360 °C). Optical rotations were measured with a Perkin–Elmer 343. High resolution mass spectra 
of new compounds were acquired on a Bruker Daltonics HR QqTOF Impact II mass spectrometer (Billerica, 
MA, USA). The nebulizer gas (N
2
) pressure was set to 1.4 bar, and the drying gas (N
2
) flow rate was set to 
4.0 L/min at a temperature of 200 °C. The capillary voltage was set to 4500 V and the charging voltage was set 
to 2000 V. Tested compounds have ≥95 % purity as determined by LCMS.
Synthesis and characterization of compounds 5 and 6 were carried out according to the previously 
reported procedures [28].
General procedure for the synthesis of benzyl-protected C-glucosyl chalcones
Compound 6 was dissolved in 1,4-dioxane (0.667  mmol in 8  mL) and the appropriate benzaldehyde 
(0.734 mmol, 1.1 eq.) was added. The mixture was stirred until fully homogenized. Then, an aqueous solu-
tion of NaOH 50 % (w/v, 8 mL) was slowly added and the mixture was stirred under reflux for 18 h–24 h. All 
reactions were followed by LCMS. Once the starting material was fully consumed, the mixture was allowed 
to reach room temperature. The reaction was quenched using HCl 2 M, washed with brine and extracted with 
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EtOAc (3 × 15  mL). The organic layers were combined, dried over MgSO
4
, filtered and concentrated under 
vacuum. The residue was purified using the most adequate purification method(s) to afford compounds 7–20.
(2E)-1-[4,6-dibenzyloxy-2-hydroxy-3-(2,3,4,6-tetra-O-benzyl-β-d-glucopyranosyl)]phenyl-3-phenyl-
prop-2-en-1-one (7): Purified by column chromatography (cyclohexane/THF 1:0 → 17:3). Isolated yield: 
72 %; LCMS: r.t. = 1.95 min (high pH method); physical appearance: yellow oil; 1H NMR (CDCl
3
) δ (ppm) 14.86, 
14.62 (s, 1H, OH-2′)*, 7.86–7.75, 7.73–7.59 (olefinic AB system, 2H, J
trans
 = 15.4  Hz, H-2 and H-3)*, 7.49–7.92 (m, 
35H, benzyl aromatics, H-2″, H-3″, H-4″, H-5″, H-6″), 6.07, 6.02 (s, 1H, H-5′)*, 5.14–4.83 (m, 8H, Ph-CH
2
, H-1″′), 
4.72–4.48 (m, 5H, Ph-CH
2
; part A of AB system, H-4″′), 4.36–4.24 (m, 2H, Ph-CH
2
; part B of AB system, H-2″′), 
3.84–3.60 (m, 4H, H-3″′, H-5″′, H-6″′a and H-6″′b). 13C NMR (CDCl
3
) δ (ppm) 193.1, 193.0 (C-1)*, 166.9, 166.1 
(C-2′)*, 164.4, 163.6 (C-4′)*, 162.2, 162.0 (C-6′)*, 142.9, 142.6 (C-3)*, 139.1, 139.0, 138.6, 138.5, 138.4, 136.4, 136.2, 
135.4, 135.3 (benzyl C
q
-aromatics)*, 129.9–127.0 (benzyl CH-aromatics, C-1″, C-2″, C-3″, C-4″, C-5″, C-6″ and C-2), 
107.5, 107.1 (C-3′)*, 106.7, 106.1 (C-1′)*, 89.3, 89.1 (C-5′)*, 87.9 (C-5″′), 79.8, 79.4 (C-2″′)*, 79.3, 79.1 (C-4″′)*, 78.6, 
78.4 (C-3″′)*, 75.7, 75.5, 75.2, 75.0, 74.4, 74.3, 73.5, 73.4 (CH
2
-Ph)*, 72.9, 72.6 (C-1″′)*, 71.4, 71.3, 70.8, 70.6 (CH
2
-Ph)*, 
69.6, 69.5 (C-6″′)*. *Two peaks were observed due to the presence of rotamers.
(2E)-1-[4,6-dibenzyloxy-2-hydroxy-3-(2,3,4,6-tetra-O-benzyl-β-d-glucopyranosyl)]phenyl-3-[4-
(morpholin-4-yl)phenyl]prop-2-en-1-one (8): Purified by column chromatography (cyclohexane/THF 
1:0 → 3:1). Isolated yield: 67 %; LCMS: r.t. = 1.86 min (high pH method); physical appearance: orange oil; 1H 
NMR (CDCl
3
) δ (ppm) 14.68 (s, 1H, OH-2′), 7.68–7.58 (s, 2H, H-2 and H-3)*, 7.43–6.85 (m, 32H, benzyl aromatics, 
H-2″ and H-6″), 6.63–6.58 (m, 2H, H-3″ and H-5″)*, 5.98, 5.93 (s, 1H, H-5′)*, 5.06–4.74 (m, 8H, Ph-CH
2
, H-1″′), 
4.64–4.40 (m, 5H, Ph-CH
2
; part A of AB system, H-4″′), 4.28–4.17 (m, 2H, Ph-CH
2
; part B of AB system, H-2″′), 
3.74–3.53 (m, 8H, H-3″′, H-5″′, H-6″′a, H-6″′b, NCH
2
CH
2
O), 3.26–3.13 (m, 4H, NCH
2
CH
2
O)*. 13C NMR (CDCl
3
) δ 
(ppm) 191.9, 191.7 (C-1)*, 165.8, 165.0 (C-2′)*, 163.0, 162.2 (C-4′)*, 160.9, 160.7 (C-6′)*, 151.3, 151.2 (C-4″)*, 142.3, 
142.0 (C-3)*, 138.0, 137.6, 137.5, 137.4, 135.4, 135.3, 134.6, 134.5 (benzyl C
q
-aromatics)*, 129.1–125.5 (benzyl CH-aro-
matics, C-1″, C-2″ and C-6″), 123.4, 123.2 (C-2)*, 119.3 (benzyl CH-aromatics), 113.5 (C-3″ and C-5″), 106.4, 106.1 
(C-3′)*, 105.5, 105.1 (C-1′)*, 88.2, 88.1 (C-5′)*, 86.8 (C-5″′), 78.8, 78.3 (C-2″′)*, 78.2, 78.1 (C-4″′)*, 77.6, 77.3 (C-3″′)*, 
74.5, 74.1, 73.9, 73.3, 73.2, 72.4, 72.3 (CH
2
-Ph)*, 71.9, 71.5 (C-1″′)*, 70.3, 70.1, 69.9, 69.1, 68.4 (CH
2
-Ph)*, 65.2 (NCH-
2
CH
2
O), 65.6, 65.5 (C-6″′)*, 47.1, 46.3 (NCH
2
CH
2
O). *Two peaks were observed due to the presence of rotamers.
(2E)-1-[4,6-dibenzyloxy-2-hydroxy-3-(2,3,4,6-tetra-O-benzyl-β-d-glucopyranosyl)]phenyl-3-[4-(1,4-
thiamorpholin-4-yl)phenyl]prop-2-en-1-one (9): Purified by column chromatography (cyclohexane/THF 
1:0 →1:1). Isolated yield: 68 %; LCMS: r.t. = 1.86 min (lipophilic high pH method); physical appearance: orange 
oil; 1H NMR (CDCl
3
) δ (ppm) 14.62, 14.33 (s, 1H, OH-2′)*, 7.68, 7.60 (s, 2H, H-2 and H-3)*, 7.43–6.88 (m, 32H, benzyl 
aromatics, H-2″ and H-6″), 6.60–6.56 (m, 2H, H-3″ and H-5″)*, 5.98, 5.93 (s, 1H, H-5′)*, 5.04–4.74 (m, 8H, Ph-CH
2
, 
H-1″′), 4.65–4.16 (m, 7H, Ph-CH
2
, H-2″′ and H-4″′), 3.83–3.49 (m, 8H, H-3″′, H-5″′, H-6″′a, H-6″′b, NCH
2
CH
2
S), 3.66–
3.63 (m, 4H, NCH
2
CH
2
S). 13C NMR (CDCl
3
) δ (ppm) 191.9, 191.7 (C-1)*, 165.7, 165.0 (C-2′)*, 162.9, 162.0 (C-4′)*, 160.9, 
160.7 (C-6′)*, 151.4, 151.3 (C-4″)*, 142.3, 142.1 (C-3)*, 138.0, 137.8, 137.7, 137.5, 137.4, 136.9, 135.4, 135.3, 134.6, 134.5 
(benzyl C
q
-aromatics)*, 129.3–124.7 (benzyl CH-aromatics, C-1″, C-2″ and C-6″), 123.2, 122.9 (C-2)*, 119.3 (benzyl 
CH-aromatics), 114.2 (C-3″ and C-5″), 106.5, 106.2 (C-3′)*, 105.9, 105.3 (C-1′)*, 88.3, 88.2 (C-5′)*, 86.8 (C-5″′), 78.8, 
78.4 (C-2″′)*, 78.3, 78.1 (C-4″′)*, 77.5, 77.3 (C-3″′)*, 75.2, 75.0, 74.6, 74.4, 74.1, 73.9, 73.4, 72.4, 72.3 (CH
2
-Ph)*, 71.9, 71.5 
(C-1″′)*, 71.0, 70.8, 70.2 (CH
2
-Ph)*, 69.7, 69.2 (C-6″′)*, 49.8, 49.2 (NCH
2
CH
2
S)*, 25.9 (NCH
2
CH
2
S). *Two peaks were 
observed due to the presence of rotamers.
(2E)-1-[4,6-dibenzyloxy-2-hydroxy-3-(2,3,4,6-tetra-O-benzyl-β-d-glucopyranosyl)]phenyl-3-[4-
(piperidin-1-yl)phenyl]prop-2-en-1-one (10): Purified by column chromatography (iso-hexane/THF 
1:0 → 1:1). Isolated yield: 56 %; LCMS: r.t. = 1.89  min (lipophilic high pH method); physical appearance: 
orange oil; 20[ ] 11
D
= −α ° (c 0.1 CHCl
3
); 1H NMR (CDCl
3
) δ (ppm) 14.68 (s, 1H, OH-2′), 7.73–7.57 (olefinic AB system, 
2H, J
trans
 = 15.4 Hz, H-2 and H-3)*, 7.44–6.81 (m, 32H, benzyl aromatics, H-2″ and H-6″), 6.64–6.58 (m, 2H, H-3″ 
and H-5″)*, 5.98, 5.93 (s, 1H, H-5′)*, 5.05–4.16 (m, 15H, Ph-CH
2
, H-1″′, H-2″′ and H-4″′), 3.76–3.45 (m, 4H, H-3″′, 
H-5″′, H-6″′a and H-6″′b), 3.23–3.15 (m, 4H, NCH
2
), 1.62–1.54 (m, 6H, NCH
2
CH
2
CH
2
). 13C NMR (CDCl
3
) δ (ppm) 
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191.9, 191.7 (C-1)*, 165.7, 165.0 (C-2′)*, 162.8, 162.0 (C-4′)*, 160.9, 160.6 (C-6′)*, 152.2, 151.8 (C-4″)*, 142.9, 142.7 
(C-3)*, 138.1, 138.0, 137.9, 137.7, 137.4, 137.3, 136.0, 135.6, 134.7, 134.6 (benzyl C
q
-aromatics)*, 129.3–124.1 (benzyl 
CH-aromatics, C-1″, C-2″ and C-6″), 123.2, 122.9 (C-2)*, 119.3 (benzyl CH-aromatics), 113.7 (C-3″ and C-5″), 106.5, 
106.2 (C-3′)*, 105.9, 105.4 (C-1′)*, 88.3, 88.2 (C-5′)*, 86.8 (C-5″′), 78.8, 78.4 (C-2″′)*, 78.3, 78.2 (C-4″′)*, 77.5, 77.3 
(C-3″′)*, 74.5, 74.3, 74.1, 73.9, 73.5, 73.1, 72.5, 72.3 (CH
2
-Ph)*, 71.9, 71.5 (C-1″′)*, 70.5, 70.2, 69.5, 69.4 (CH
2
-Ph)*, 
69.3, 69.2 (C-6″′)*, 48.3 (NCH
2
)*, 24.4 (NCH
2
CH
2
CH
2
), 23.4 (NCH
2
CH
2
CH
2
). *Two peaks were observed due to the 
presence of rotamers.
(2E)-1-[4,6-dibenzyloxy-2-hydroxy-3-(2,3,4,6-tetra-O-benzyl-β-d-glucopyranosyl)]phenyl-3-[4-(4-tert-
butyloxycarbonylpiperazin-1-yl)phenyl]prop-2-en-1-one (11): Purified by column chromatography 
(cyclohexane/THF 1:0 → 3:1). Isolated yield: 71 %; LCMS: r.t. = 1.91 min (lipophilic high pH method); physical 
appearance: orange oil. 1H NMR (CDCl
3
) δ (ppm) 14.64 (s, 1H, OH-2′), 7.68–7.60 (s, 2H, H-2 and H-3)*, 7.42–6.82 
(m, 32H, benzyl aromatics, H-2″ and H-6″), 6.64–6.60 (m, 2H, H-3″ and H-5″)*, 5.99, 5.94 (s, 1H, H-5′)*, 5.07–4.16 
(m, 15H, Ph-CH
2
, H-1″′, H-2″′ and H-4″′), 3.89–3.46 (m, 8H, H-3″′, H-5″′, H-6″′a, H-6″′b and NCH
2
CH
2
N-Boc), 
3.32–3.30, 3.18–3.15 (m, 4H, NCH
2
CH
2
N-Boc)*, 1.43 [s, 9H, C(CH
3
)
3
]. 13C NMR (CDCl
3
) δ (ppm) 192.0, 191.7 (C-1)*, 
165.8, 165.0 (C-2′)*, 163.0, 162.2 (C-4′)*, 160.9, 160.7 (C-6′)*, 153.7 (C=O Boc), 151.2, 151.1 (C-4″)*, 143.3, 142.9 
(C-3)*, 138.0, 137.6, 137.4, 135.4, 135.3, 136.6, 134.5, 130.8 (benzyl C
q
-aromatics)*, 129.1–125.5 (benzyl CH-aromat-
ics, C-1″, C-2″ and C-6″), 123.5, 123.2 (C-2)*, 114.2, 112.8 (C-3″ and C-5″), 106.9, 106.5 (C-3′)*, 105.8, 105.2 (C-1′)*, 
88.3, 88.2 (C-5′)*, 86.8 (C-5″′), 79.1 [C(CH
3
)
3
], 78.8, 78.3 (C-2″′)*, 78.3, 78.1 (C-4″′)*, 77.5, 77.3 (C-3″′)*, 74.6, 74.4, 
74.1, 73.3, 73.2, 72.4, 72.3 (CH
2
-Ph)*, 71.9, 71.5 (C-1″′)*, 70.2 (CH
2
-Ph)*, 69.7, 69.2 (C-6″′), 47.0, 46.0 (NCH
2
CH
2
N-
Boc)*, 27.4 [C(CH
3
)
3
]. *Two peaks were observed due to the presence of rotamers. HRMS-ESI (m/z): [M + H]+ 
calcd for C
75
H
75
NO
11
 1143.5365, found 1143.5368; [M + Na]+ calcd for C
75
H
74
NNaO
11
 1165.6184, found 1165.6178.
(2E)-1-[4,6-dibenzyloxy-2-hydroxy-3-(2,3,4,6-tetra-O-benzyl-β-d-glucopyranosyl)]phenyl-3-[4-
(4-methylpiperazin-1-yl)phenyl]prop-2-en-1-one (12): Purified by precipitation in cold methanol, fol-
lowed by filtration under reduced pressure. Isolated yield: 63 %; LCMS: r.t. = 1.87  min (lipophilic high pH 
method); physical appearance: orange solid; m.p. = 52.7–55.2°C; 20[ ] 14
D
α = − ° (c 0.1 CHCl
3
); 1H NMR (CDCl
3
) 
δ (ppm) 14.33, 14.14 (s, 1H, OH-2′)*, 7.69–7.61 (s, 2H, H-2 and H-3)*, 7.43–6.83 (m, 32H, benzyl aromatics, H-2″ 
and H-6″), 6.65–6.62 (m, 2H, H-3″ and H-5″)*, 5.99, 5.94 (s, 1H, H-5′)*, 5.05–4.13 (m, 15H, Ph-CH
2
, H-1″′, H-2″′ 
and H-4″′), 3.76–3.50 (m, 4H, H-3″′, H-5″′, H-6″′a and H-6″′b) 3.35–3.33, 3.24–3.21 (m, 4H, NCH
2
CH
2
NCH
3
)*, 
2.51–2.46 (m, 4H, NCH
2
CH
2
NCH
3
)*, 2.28 (s, 3H, NCH
3
). 13C NMR (CDCl
3
) δ (ppm) 192.0, 191.7 (C-1)*, 165.6, 165.1 
(C-2′)*, 162.9, 162.2 (C-4′)*, 161.9, 160.9 (C-6′)*, 151.3, 151.2 (C-4″)*, 142.5, 142.3 (C-3)*, 138.1, 137.9, 137.5, 137.4, 
136.7, 135.4, 135.2, 134.6, 134.5, 130.8 (benzyl C
q
-aromatics and C-1″)*, 129.1–124.9 (benzyl CH-aromatics, C-2″ 
and C-6″), 123.1, 122.8 (C-2)*, 113.7, 112.5 (C-3″ and C-5″), 109.9, 107.8 (C-3′)*, 106.5, 105.9 (C-1′)*, 88.3, 88.2 (C-5′)*, 
86.8 (C-5″′), 78.8, 78.4 (C-2″′)*, 78.3, 78.1 (C-4″′)*, 77.5, 77.3 (C-3″′)*, 74.6, 74.4, 74.1, 73.4, 73.3, 73.2, 72.4, 72.3 (CH
2
-
Ph)*, 71.9, 71.5 (C-1″′)*, 70.2 (CH
2
-Ph), 69.6, 69.2 (C-6″′), 53.8, 53.7 (NCH
2
CH
2
NCH
3
)*, 46.8, 46.1 (NCH
2
CH
2
NCH
3
)*, 
45.2, 45.1(NCH3)*. *Two peaks were observed due to the presence of rotamers. HRMS-ESI (m/z): [M + H]+ calcd 
for C
68
H
69
N
2
O
9
 1057.4998, found 1057.5002; [M + Na]+ calcd for C
68
H
68
N
2
NaO
9
 1079.4817, found 1079.4825.
(2E)-1-[4,6-dibenzyloxy-2-hydroxy-3-(2,3,4,6-tetra-O-benzyl-β-d-glucopyranosyl)]phenyl-3-[4-
(4-methylpiperazin-1-yl)methylphenyl]prop-2-en-1-one (13): Purified by filtration through an Isolute 
SCX-2 column (Biotage). Isolated yield: 58 %; LCMS: r.t. = 1.89  min (lipophilic high pH method); physical 
appearance: orange oil. 1H NMR (CDCl
3
) δ (ppm) 14.85, 14.25 (s, 1H, OH-2′)*, 7.86–7.72 (olefinic AB system, 2H, 
J
trans
 = 15.6 Hz, H-2 and H-3)*, 7.50–6.95 (m, 34H, benzyl aromatics, H-2″, H-3″, H-5″ and H-6″)*, 6.07, 6.02 (s, 
1H, H-5′)*, 5.15–4.83 (m, 8H, Ph-CH
2
, H-1″′), 4.70–4.45 (m, 5H, Ph-CH
2
; part A of AB system, H-4″′), 4.36–4.24 
(m, 2H, Ph-CH
2
; part B of AB system, H-2″′), 3.84–3.59 (m, 4H, H-3″′, H-5″′, H-6″′a and H-6″′b), 3.48 (s, 2H, 
PhCH
2
N), 2.46 (br s, 8H, NCH
2
CH
2
NCH
3
), 2.27 (s, 3H, NCH
3
). 13C NMR (CDCl
3
) δ (ppm) 192.9, 192.0 (C-1)*, 166.8, 
166.1 (C-2′)*, 162.9, 162.2 (C-4′)*, 162.1, 161.9 (C-6′)*, 143.3, 142.7 (C-3)*, 141.3, 140.3, 139.1, 139.0, 138.5, 138.4, 
137.3, 136.9, 136.3, 136.2, 135.5, 135.3, (benzyl C
q
-aromatics and C-4″)*, 134.1, 133.3 (C-2)*, 129.8–126.6 (benzyl 
CH-aromatics, C-1″, C-2″, C-3″, C-5″ and C-6″), 107.5, 107.2 (C-3′)*, 106.8, 106.1 (C-1′)*, 89.3, 89.2 (C-5′)*, 87.9 
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(C-5″′), 79.8, 79.3 (C-2″′)*, 79.3, 79.1 (C-4″′)*, 78.6, 78.3 (C-3″′)*, 75.6, 75.5, 75.1, 75.0, 74.4, 74.3, 73.5, 73.3 (CH
2
-
Ph)*, 72.8, 72.5 (C-1″′)*, 71.4, 71.3, 70.7, 70.2 (CH
2
-Ph)*, 69.3 (C-6″′), 62.7, 62.6 (PhCH
2
N)*, 55.1 (NCH
2
CH
2
N)*, 
46.0 (NCH
3
)*. *Two peaks were observed due to the presence of rotamers. HRMS-ESI (m/z): [M + H]+ calcd for 
C
69
H
71
N
2
O
9
 1071.5154, found 1071.5152; [M + Na]+ calcd for C
69
H
70
N
2
NaO
9
 1093.4974, found 1093.4965.
(2E)-1-[4,6-dibenzyloxy-2-hydroxy-3-(2,3,4,6-tetra-O-benzyl-β-d-glucopyranosyl)]phenyl-3-[2-fluoro-
4-(morpholin-4-yl)phenyl]prop-2-en-1-one (14): Purified by column chromatography (cyclohexane/THF 
1:0 → 3:2). Isolated yield: 61 %; LCMS: r.t. = 1.85  min (lipophilic high pH method); physical appearance: 
orange oil; 20[ ] 10
D
α = − ° (c 0.1 CHCl
3
); 1H NMR (CDCl
3
) δ (ppm) 14.87, 14.55 (s, 1H, OH-2′)*, 7.93–7.68 (olefinic 
AB system, 2H, J
trans
 = 15.9 Hz, H-2 and H-3)*, 7.48–6.83 (m, 31H, benzyl aromatics and H-6″), 6.49–6.39 (m, 2H, 
H-3″ and H-5″), 6.04, 5.99 (s, 1H, H-3′)*, 5.11–5.83 (m, 8H, Ph-CH
2
, H-1″′), 4.70–4.48 (m, 5H, Ph-CH
2
; part A 
of AB system, H-4″′), 4.35–4.24 (m, 2H, Ph-CH
2
; part B of AB system, H-2″′), 3.86–3.57 (m, 8H, H-3″′, H-5″′, 
H-6″′a, H-6″′b, NCH
2
CH
2
O), 3.23–3.20, 3.15–3.13 (m, 4H, NCH
2
CH
2
O)*. 13C NMR (CDCl
3
) δ (ppm) 193.0, 192.8 
(C-1)*, 166.6, 165.9 (C-2′)*, 164.1, 163.3 (C-4′)*, 163.0, 162.7 (d, J
C-F
 = 252.7 Hz, C-2″)*, 161.9, 161.7 (C-6′)*, 153.7, 153.6 
(d, J
C-F
 = 11.1 Hz, C-4″)*, 139.1, 139.0, 138.6, 138.5, 138.4, 136.4, 136.3, 135.8, 135.7 (benzyl C
q
-aromatics)*, 135.5, 
135.2 (C-3)*, 129.6–127.0 (benzyl CH-aromatics, C-6″), 126.0, 125.9 (d, J
C-F
 = 4.3 Hz C-2)*, 114.0 (d, J
C-F
 = 12.4 Hz, 
C-1″), 110.2 (C-5″), 107.5, 107.1 (C-3′)*, 107.0, 106.4 (C-1′)*, 101.3, 101.2 (d, J
C-F
 = 26.3 Hz, C-3″)*, 89.5, 89.4 (C-5′)*, 
87.8 (C-5″′), 79.8, 79.4 (C-2″′)*, 79.3, 79.1 (C-4″′)*, 78.6, 78.3 (C-3″′)*, 75.6, 75.5, 75.2, 75.0, 74.3, 73.5, 73.3 (CH
2
-
Ph)*, 72.9, 72.5 (C-1″′)*, 71.2, 71.1, 70.7, 70.1 (CH
2
-Ph)*, 69.4 (C-6″′), 66.7 (NCH
2
CH
2
O), 48.8, 47.8 (NCH
2
CH
2
O). 
19F NMR (CDCl
3
) δ (ppm) −112.57, −112.77 (dd, J
F-H-5″
 = 13.7 Hz, J
F-H-2″
 = 8.2 Hz).**Two peaks were observed due 
to the  presence of rotamers. HRMS-ESI (m/z): [M + H]+ calcd for C
67
H
65
FNO
10
 1062.4584, found 1062.4594; 
[M + Na]+ calcd for C
67
H
64
FNNaO
10
 1084.4406, found 1084.4406.
(2E)-1-[4,6-dibenzyloxy-2-hydroxy-3-(2,3,4,6-tetra-O-benzyl-β-d-glucopyranosyl)]phenyl-3-[3-fluoro-
4-(morpholin-4-yl)phenyl]prop-2-en-1-one (15): Purified by column chromatography (cyclohexane/
THF 1:0 → 3:2). Isolated yield: 76 %; LCMS: r.t. = 1.89 min (lipophilic high pH method); physical appear-
ance: yellow solid; m.p. = 68.6–70.4 °C; 20[ ] 9
D
α = − ° (c 0.1 CHCl
3
); 1H NMR (CDCl
3
) δ (ppm) 14.85, 14.52 (s, 1H, 
OH-2′)*, 7.74–7.53 (olefinic AB system, 2H, J
trans
 = 15.6 Hz, H-2 and H-3)*, 7.49–6.90 (m, 31H, benzyl aromat-
ics and H-5″), 6.78–6.72 (m, 2H, H-2″ and H-6″), 6.07, 6.01 (s, 1H, H-5′)*, 5.14–5.82 (m, 8H, Ph-CH
2
, H-1″′), 
4.73–4.45 (m, 5H, Ph-CH
2
; part A of AB system, H-4″′), 4.36–4.24 (m, 2H, Ph-CH
2
; part B of AB system, H-2″′), 
3.89–3.57 (m, 8H, H-3″′, H-5″′, H-6″′a, H-6″′b, NCH
2
CH
2
O), 3.27–3.24, 3.15–3.13 (m, 4H, NCH
2
CH
2
O)*. 13C NMR 
(CDCl
3
) δ (ppm) 193.2, 192.6 (C-1)*, 166.5, 166.9 (C-2′)*, 164.2, 164.1 (C-4′)*, 162.8, 162.7 (d, J
C-F
 = 253.3  Hz, 
C-3″)*, 162.1, 161.7 (C-6′)*, 151.1, 150.9 (d, J
C-F
 = 11.2 Hz, C-4″)*, 141.6, 141.4 (C-3)*, 139.1, 139.0, 138.7, 138.6, 
138.5, 138.4, 136.4, 136.2, 135.8, 135.6 (benzyl C
q
-aromatics)*, 129.7–126.9 (benzyl CH-aromatics and, C-1″ and 
C-6″), 126.4, 126.2 (d, J
C-F
 = 4.5 Hz C-2)*, 118.1 (C-5″), 115.0, 114.9 (d, J
C-F
 = 22.3 Hz, C-2″)*, 107.4, 107.0 (C-3′)*, 
106.8, 106.5 (C-1′)*, 89.6, 89.4 (C-5′)*, 87.8 (C-5″′), 79.9, 79.3 (C-2″′)*, 79.3, 79.1 (C-4″′)*, 78.5, 78.3 (C-3″′)*, 75.4, 
75.4, 75.1, 74.9, 74.3, 73.5, 73.3 (CH
2
-Ph)*, 72.8, 72.5 (C-1″′)*, 71.4, 71.1, 70.2, 69.4 (CH
2
-Ph)*, 69.4 (C-6″′), 66.9 
(NCH
2
CH
2
O), 50.7, 50.5 (NCH
2
CH
2
O)*. 19F NMR (CDCl
3
) δ (ppm) −123.20 (dd, J
F-H-6″
 = 13.8 Hz, J
F-H-3″
 = 8.1 Hz). 
*Two peaks were observed due to the presence of rotamers. HRMS-ESI (m/z): [M + H]+ calcd for C
67
H
65
FNO
10
 
1062.4584, found 1062.4593; [M + Na]+ calcd for C
67
H
64
FNNaO
10
 1084.4406, found 1084.4414.
(2E)-1-[4,6-dibenzyloxy-2-hydroxy-3-(2,3,4,6-tetra-O-benzyl-β-d-glucopyranosyl)]phenyl-3-[3-bromo-
4-(morpholin-4-yl)phenyl]prop-2-en-1-one (16): Purified by column chromatography (cyclohexane/THF 
1:0 → 13:7). Isolated yield: 76 %; LCMS: r.t. = 2.01 min (lipophilic high pH method); physical appearance: red 
solid; m.p. = 65.8–68.5 °C; 20[ ] 6
D
α = − ° (c 0.1 CHCl
3
); 1H NMR (CDCl
3
) δ (ppm) 14.67, 14.34 (s, 1H, OH-2′)*, 7.75–7.56 
(olefinic AB system, 2H, J
trans
 = 15.6 Hz, H-2 and H-3)*, 7.53–6.93 (m, 31H, benzyl aromatics and H-5″), 6.85–6.81 
(m, 2H, H-2″ and H-6″), 6.06, 6.01 (s, 1H, H-5′)*, 5.15–5.83 (m, 8H, Ph-CH
2
, H-1″′), 4.71–4.48 (m, 5H, Ph-CH
2
; 
part A of AB system, H-4″′), 4.35–4.23 (m, 2H, Ph-CH
2
; part B of AB system, H-2″′), 3.91–3.57 (m, 8H, H-3″′, 
H-5″′, H-6″′a, H-6″′b, NCH
2
CH
2
O), 3.11–3.08 (m, 4H, NCH
2
CH
2
O). 13C NMR (CDCl
3
) δ (ppm) 192.8, 192.6 (C-1)*, 
166.5, 166.8 (C-2′)*, 164.5, 164.4 (C-4′)*, 162.0, 161.8 (C-6′)*, 151.6 (C-4″)*, 140.8, 140.5 (C-3)*, 139.1, 139.0, 138.5, 
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138.4, 136.3, 136.2, 135.4, 135.3, 134.0, 131.7 (benzyl C
q
-aromatics)*, 129.0–127.0 (benzyl CH-aromatics and, C-1″, 
C-2″, C-6″ and C-2), 120.5 (C-5″)*, 119.3 (C-3″)*, 107.5, 107.2 (C-3′)*, 106.3, 106.1 (C-1′)*, 89.5, 89.3 (C-5′)*, 87.9, 87.8 
(C-5″′)*, 79.8, 79.3 (C-2″′)*, 79.3, 79.1 (C-4″′)*, 78.5, 78.3 (C-3″′)*, 75.6, 75.5, 75.1, 75.0, 74.3, 73.5, 73.3, (CH
2
-Ph)*, 
72.8, 72.5 (C-1″′)*, 71.4, 71.2, 70.7, 70.3 (CH
2
-Ph)*, 69.4 (C-6″′), 67.0 (NCH
2
CH
2
O), 51.8 (NCH
2
CH
2
O)*. *Two peaks 
were observed due to the presence of rotamers.
(2E)-1-[4,6-dibenzyloxy-2-hydroxy-3-(2,3,4,6-tetra-O-benzyl-β-d-glucopyranosyl)]phenyl-3-[3-
(morpholin-4-yl)phenyl]prop-2-en-1-one (17): Purified by column chromatography (cyclohexane/THF 
1:0 → 3:2). Isolated yield: 40 %; LCMS: r.t. = 1.89 min (lipophilic high pH method); physical appearance: 
orange oil; 20[ ] 8
D
α = − ° (c 0.1 CHCl
3
); 1H NMR (CDCl
3
) δ (ppm) 14.70, 14.36 (s, 1H, OH-2′)*, 7.86–7.72 (olefinic 
AB system, 2H, J
trans
 = 16.5 Hz, H-2 and H-3)*, 7.49–6.94 (m, 32H, benzyl aromatics, H-5″), 6.89–6.85 (m, 2H, 
H-2″, H-4″)*, 6.62–6.59 (m, 1H, H-6″)*, 6.06, 6.01 (s, 1H, H-5′)*, 5.12–4.86 (m, 8H, Ph-CH
2
, H-1″′), 4.69–4.48 
(m, 5H, Ph-CH
2
; part A of AB system, H-4″′), 4.35–4.23 (m, 2H, Ph-CH
2
; part B of AB system, H-2″′), 3.83–
3.57 (m, 8H, H-3″′, H-5″′, H-6″′a, H-6″′b, NCH
2
CH
2
O), 3.13–3.10, 3.06–3.03 (m, 4H, NCH
2
CH
2
O)*. 13C NMR 
(CDCl
3
) δ (ppm) 193.2, 193.0 (C-1)*, 166.5, 165.8 (C-2′)*, 164.3, 163.5 (C-4′)*, 162.1, 161.9 (C-6′)*, 151.5, 151.4 
(C-3″)*, 143.3 (C-3), 143.1 (C-1″), 139.1, 139.0, 138.6, 138.5, 138.4, 138.3, 136.4, 136.2, 135.5, 135.4 (benzyl C
q
-
aromatics)*, 127.4–127.0 (benzyl CH-aromatics, C-2 and C-5″), 119.4, 119.3 (C-6″)*, 117.4, 117.3 (C-4″)*, 116.4, 
116.3 (C-2″)*, 107.5, 107.1 (C-3′)*, 107.0, 106.4 (C-1′)*, 89.5, 89.3 (C-5′)*, 87.8 (C-5″′)*, 79.8, 79.3 (C-2″′)*, 79.3, 
79.1 (C-4″′)*, 78.6, 78.3 (C-3″′)*, 75.6, 75.5, 75.2, 75.0, 74.4, 74.3 (CH
2
-Ph)*, 72.9, 72.5 (C-1″′)*, 71.2 (CH
2
-Ph)*, 
70.8, 70.2 (C-6″′)*, 69.4 (CH
2
-Ph), 66.9 (NCH
2
CH
2
O), 49.1 (NCH
2
CH
2
O). *Two peaks were observed due to the 
presence of rotamers. HRMS-ESI (m/z): [M + H]+ calcd for C
67
H
66
NO
10
 1044.4681, found 1044.4681; [M + Na]+ 
calcd for C
67
H
65
NNaO
11
 1066.4501, found 1066.4500.
(2E)-1-[4,6-dibenzyloxy-2-hydroxy-3-(2,3,4,6-tetra-O-benzyl-β-d-glucopyranosyl)]phenyl-3-[2-
(morpholin-4-yl)phenyl]prop-2-en-1-one (18): Purified by column chromatography (cyclohexane/THF 
1:0 → 4:1). Isolated yield: 55 %; LCMS: r.t. = 1.89  min (lipophilic high pH method); physical appearance: 
orange solid; m.p. = 70.1–71.1 °C; 20[ ] 7
D
α = − ° (c 0.1 CHCl
3
); 1H NMR (CDCl
3
) δ (ppm) 14.66, 14.34 (s, 1H, OH-2′)*, 
8.10–7.97 (part A of olefinic AB system, 1H, J
trans
 = 15.4 Hz, H-3)*, 7.72–7.59 (part B of olefinic AB system, 1H, 
J
trans
 = 15.8  Hz, H-2)*, 7.42–6.89 (m, 33H, benzyl aromatics, H-3″, H-4″ and H-5″), 6.78–6.72 (m, 1H, H-6″)*, 
6.00, 5.94 (s, 1H, H-5′)*, 5.06–4.73 (m, 8H, Ph-CH
2
, H-1″′), 4.64–4.40 (m, 5H, Ph-CH
2
; part A of AB system, 
H-4″′), 4.30–4.18 (m, 2H, Ph-CH
2
; part B of AB system, H-2″′), 3.84–3.50 (m, 8H, H-3″′, H-5″′, H-6″′a, H-6″′b, 
NCH
2
CH
2
O), 2.93–2.90, 2.85–2.79 (m, 4H, NCH
2
CH
2
O)*. 13C NMR (CDCl
3
) δ (ppm) 192.4, 192.1 (C-1)*, 165.4, 164.8 
(C-2′)*, 163.2, 162.3 (C-4′)*, 160.9, 160.7 (C-6′)*, 151.7, 151.6 (C-2″)*, 139.4, 138.8 (C-3)*, 138.6, 138.0, 137.9, 137.6, 
137.5, 137.4, 135.3, 135.2, 134.3, 134.2, 129.5, 128.5 (benzyl C
q
-aromatics)*, 127.9–124.1 (benzyl CH-aromatics, C-2, 
C-1″ and C-4″), 122.3, 122.0 (C-6″)*, 119.6, 119.4 (C-5″)*, 117.4 (C-3″)*, 106.5, 106.2 (C-3′)*, 106.0, 105.3 (C-1′)*, 88.2, 
88.1 (C-5′)*, 86.8 (C-5″′)*, 78.8, 78.3 (C-2″′)*, 78.3, 78.1 (C-4″′)*, 77.5, 77.1 (C-3″′)*, 74.6, 74.5, 74.1, 73.9, 73.3, 72.4, 
72.3 (CH
2
-Ph)*, 71.9, 71.5 (C-1″′)*, 70.3, 70.2 (CH
2
-Ph)*, 69.7, 69.2 (C-6″′)*, 68.4 (CH
2
-Ph), 66.2, 66.1 (NCH
2
CH
2
O)*, 
52.2 (NCH
2
CH
2
O). *Two peaks were observed due to the presence of rotamers. HRMS-ESI (m/z): [M + H]+ calcd 
for C
67
H
66
NO
10
 1044.4681, found 1044.4677; [M + Na]+ calcd for C
67
H
65
NNaO
11
 1066.4501, found 1066.4497.
(2E)-1-[4,6-dibenzyloxy-2-hydroxy-3-(2,3,4,6-tetra-O-benzyl-β-d-glucopyranosyl)]phenyl-3-[(4-
dimethylamino)phenyl]prop-2-en-1-one (19): Purified by column chromatography (cyclohexane/THF 
1:0 → 3:2). Isolated yield: 55 %; LCMS: r.t. = 1.91  min (lipophilic high pH method); physical appearance: 
orange solid; m.p. = 168.8–169.4 °C; 20[ ] 15
D
α = − ° (c 0.1 CHCl
3
); 1H NMR (CDCl
3
) δ (ppm) 14.83 (s, 1H, OH-2′), 
7.83–7.64 (olefinic AB system, 2H, J
trans
 = 15.5 Hz, H-2 and H-3)*, 7.52–6.95 (m, 32H, benzyl aromatics, H-2″ and 
H-6″), 6.52–6.49 (m, 2H, H-3″ and H-5″)*, 6.05, 6.01 (s, 1H, H-5′)*, 5.15–4.83 (m, 8H, Ph-CH
2
, H-1″′), 4.74–4.46 
(m, 5H, Ph-CH
2
; part A of AB system, H-4″′), 4.36–4.25 (m, 2H, Ph-CH
2
; part B of AB system, H-2″′), 3.84–3.58 
(m, 4H, H-3″′, H-5″′, H-6″′a, H-6″′b), 3.01, 3.00 [N(CH
3
)
2
]*. 13C NMR (CDCl
3
) δ (ppm) 192.9, 192.7 (C-1)*, 166.8, 
166.1 (C-2′)*, 163.7, 163.0 (C-4′)*, 161.9, 161.7 (C-6′)*, 151.7, 151.6 (C-4″)*, 144.4, 144.2 (C-3)*, 139.1, 139.0, 138.8, 
138.6, 138.5, 138.3, 136.5, 136.4, 135.7, 130.5, 130.4 (benzyl C
q
-aromatics)*, 129.0–126.9 (benzyl CH-aromatics, 
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C-2″ and C-6″), 123.3 (C-1″), 122.5, 122.3 (C-2)*, 111.7, 111.0 (C-3″ and C-5″)*, 107.5, 107.2 (C-3′)*, 107.0, 106.4 (C-1′)*, 
89.4, 89.2 (C-5′)*, 87.8 (C-5″′), 79.9, 79.4 (C-2″′)*, 79.3, 79.1 (C-4″′)*, 78.6, 78.4 (C-3‴)*, 75.6, 75.5, 75.1, 75.0, 74.4, 
74.3, 73.5, 73.3 (CH
2
-Ph)*, 73.0, 72.6 (C-1‴)*, 73.1, 71.2, 70.7, 70.2 (CH
2
-Ph)*, 69.4 (C-6‴), 40.2, 40.1 [N(CH
2
)
3
]. *Two 
peaks were observed due to the presence of rotamers. HRMS-ESI (m/z): [M + H]+ calcd for C
65
H
64
NO
9
 1002.4576, 
found 1002.4579; [M + Na]+ calcd for C
65
H
63
NNaO
9
 1024.4395, found 1024.4399.
(2E)-1-[4,6-dibenzyloxy-2-hydroxy-3-(2,3,4,6-tetra-O-benzyl-β-d-glucopyranosyl)]phenyl-3-[(4-diphe-
nylamino)phenyl]prop-2-en-1-one (20): Purified by column chromatography (cyclohexane/THF 1:0 → 7:3). 
Isolated yield: 74 %; LCMS: r.t. = 1.92  min (lipophilic high pH method); physical appearance: orange oil; 
20[ ] 5
D
α = − ° (c 0.1 CHCl
3
); 1H NMR (CDCl
3
) δ (ppm) 14.68, 14.40 (s, 1H, OH-2′)*, 7.78–7.71, 7.69–7.63 (olefinic AB 
system, 2H, J
trans
 = 15.6 Hz, H-2 and H-3)*, 7.49–6.95 (m, 42H, benzyl aromatics, NPh
2
, H-2″ and H-6″), 6.84–6.80 
(m, 2H, H-3″ and H-5″)*, 6.05, 6.00 (s, 1H, H-5′)*, 5.13–4.81 (m, 8H, Ph-CH
2
, H-1‴), 4.73–4.45 (m, 5H, Ph-CH
2
; 
part A of AB system, H-4‴), 4.36–4.24 (m, 2H, Ph-CH
2
; part B of AB system, H-2‴), 3.83–3.56 (m, 4H, H-3‴, 
H-5‴, H-6‴a, H-6‴b). 13C NMR (CDCl
3
) δ (ppm) 192.9, 192.7 (C-1)*, 166.8, 166.1 (C-2′)*, 164.1, 164.0 (C-4′)*, 163.3, 
162.0 (C-6′)*, 149.7, 149.6 (C-4″)*, 146.9 (C
q
-Ph), 142.8, 142.6 (C-3)*, 139.0, 138.7, 138.5, 136.5, 136.3, 135.4, 135.3 
(benzyl C
q
-aromatics)*, 129.6–126.9 (benzyl CH-aromatics, C-1″, C-2″ and C-6″), 125.3 (C-2)*, 124.0, 123.9 (benzyl 
CH-aromatics)*, 121.7, 121.3 (C-3″ and C-5″)*, 107.9, 107.5 (C-3′)*, 106.2, 106.0 (C-1′)*, 89.3 (C-5′)*, 87.8 (C-5‴), 79.9, 
79.4 (C-2‴)*, 79.3, 79.1 (C-4‴)*, 78.5, 78.4 (C-3‴)*, 75.6, 75.5, 75.1, 75.0, 74.4, 74.3, 73.5, 73.3 (CH
2
-Ph)*, 73.1, 72.9 
(C-1‴)*, 71.3, 71.2, 70.7, 70.2 (CH
2
-Ph)*, 69.4 (C-6‴). *Two peaks were observed due to the presence of rotamers. 
HRMS-ESI (m/z): [M + H]+ calcd for C
75
H
68
NO
9
 1126.4884, found 1126.4890.
General procedure for the synthesis of C-glucosyl flavones
Each C-glucosyl chalcone 7–20 was dissolved in dry pyridine (0.172 mmol in 5.11 mL). Then, catalytic amounts 
of I
2
 (0.060 mmol, 0.35 eq.) were added and the mixture was stirred under reflux for 48 h–72 h. All reactions 
were followed by LCMS. Once the starting material was fully consumed, the mixture was allowed to reach 
room temperature and the pyridine was co-evaporated with toluene under reduced pressure. The residue 
was resuspended in dichloromethane, washed first with a saturated solution of sodium thiosulfate, and then 
with brine. The flavone was extracted with dichloromethane (3 × 30 mL), dried over MgSO
4
, and the solution 
filtered and concentrated under vacuum. The residue was then resuspended in extra dry dichloromethane 
(7.10 mL) and stirred at −78 °C under N
2
 saturated atmosphere. A 1 M solution of BBr
3
 in dichloromethane 
(1.72 mmol, 10 eq.) was added in a dropwise manner over 5 min, and the reaction stirred for 2 h–4 h. After 
having reached completion by LCMS, the reaction was quenched with a 1:1  mixture of dichloromethane/
methanol (ca. 15 mL) and the reaction was stirred for approximately 20 min at room temperature. The solvent 
was evaporated under vacuum and the residue purified using the most adequate purification method(s) to 
afford compounds 1 and 21–32.
5,7-Dihydroxy-8-(β-d-glucopyranosyl)-4′-(morpholin-4-yl)flavone (1): Purified by preparative HPLC. 
Reaction yield over two steps: 74 %; LCMS: r.t. = 0.57 min, m/z = 500.0 [M–H]− (high pH method); physical 
appearance: orange solid; m.p. = 210.5–211.4 °C; 20[ ] 10
D
α = + ° (c 0.5 MeOH); 1H NMR (MeOD) δ (ppm) 7.94, 7.84 
(d, 2H, J
ortho
 = 8.3 Hz, H-2′ and H-6′)*, 7.01 (d, 2H, J
ortho
 = 8.6 Hz, H-3′ and H-5′), 6.52 (s, 1H, H-3), 6.26 (s, 1H, 
H-6), 5.05, 4.99 (d, 1H, J
1″-2″
 = 9.9 Hz, H-1″)*, 4.14 (t, 1H, J
2″-1″∼2″-3″
 = 9.5 Hz, H-2″), 3.98–3.69 (m, 6H, H-6″a, H-6″b 
and NCH
2
CH
2
O), 3.70 (t, 1H, J
4″-3″∼4″-5″
 = 9.6 Hz, H-4″), 3.56–3.54 (m, 1H, H-3″), 3.50–3.45 (m, 1H, H-5″), 3.32–3.20 
(NCH
2
CH
2
O, superimposed with the MeOD peak). 13C NMR (MeOD) δ (ppm) 184.8 (C-4), 166.7 (C-2), 164.7 (C-7), 
162.8 (C-5), 152.3 (C-8a), 155.3 (C-4′), 129.7 (C-2′ and C-6′), 122.3 (C-1′), 115.5 (C-3′ and C-5′), 106.0 (C-4a), 105.4 
(C-8), 103.2 (C-3), 99.6 (C-6), 83.1 (C-5″), 80.5 (C-3″), 75.5 (C-1″), 73.1 (C-2″), 72.3 (C-4″), 67.9 (NCH
2
CH
2
O), 63.0 
(C-6″), 47.1 (NCH
2
CH
2
O). *Two peaks were observed due to the presence of rotamers. HRMS-ESI (m/z): [M + H]+ 
calcd for C
25
H
28
NO
10
 502.1708, found 502.1695.
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5,7-Dihydroxy-8-(β-d-glucopyranosyl)flavone (21): Purified by preparative HPLC, followed by Isolute SCX-2 
column chromatography (Biotage). Reaction yield over two steps: 88 %; LCMS: r.t. = 0.49 min, m/z = 414.80 
[M–H]− (high pH method); physical appearance: yellow solid; m.p. = 188.1–189.2 °C. 1H NMR (MeOD) δ (ppm) 
8.12, 8.02 (d, 2H, J
ortho
 = 7.1 Hz, H-2′ and H-6′)*, 7.58–7.54 (m, 3H, H-3′, H-4′ and H-5′), 6.75 (s, 1H, H-3), 6.30 (s, 1H, 
H-6), 5.09, 5.02 (d, 1H, J
1″-2″
 = 9.9 Hz, H-1″)*, 4.13 (t, 1H, J
2″-1″∼2″-3″
 = 9.3 Hz, H-2″), 3.99, 3.93 (br d, 1H, J
6″a-6″b
 = 12.1 Hz, 
H-6″a)*, 3.83 (dd, 1H, J
6″b-6″a
 = 12.1 Hz, J
6″b-5″
 = 5.3 Hz, H-6″a), 3.69 (t, 1H, J
4″-3″∼4″-5″
 = 9.2 Hz, H-4″), 3.57–3.48 (m, 2H, 
H-3″ and H-5″). 13C NMR (MeOD) δ (ppm) 182.8 (C-4), 164.6 (C-2), 163.4 (C-7), 161.3 (C-5), 156.8 (C-8a), 131.6 (C-3′ 
and C-5′), 131.3 (C-1′), 128.8 (C-4′), 126.6, 126.3 (C-2′ and C-6′)*, 104.6 (C-4a), 104.3 (C-3), 103.9 (C-8), 98.2 (C-6), 
81.5 (C-5″), 78.8 (C-3″), 73.9 (C-1″), 71.4 (C-2″), 70.9, 70.1 (C-4″)*, 61.7, 61.2 (C-6″)*. *Two peaks were observed due 
to the presence of rotamers. HRMS-ESI (m/z): [M + H]+ calcd for C
21
H
21
O
9
 417.1180, found 417.1174.
5,7-Dihydroxy-8-(β-d-glucopyranosyl)-4′-(1,4-thiazinnan-4-yl)flavone (22): Purified by preparative 
HPLC followed by SFCMS (naphthyl column). Reaction yield over two steps: 24 %; LCMS: r.t. = 0.70  min, 
m/z = 518.2 [M + H]+ (high pH method); physical appearance: yellow solid; 1H NMR (MeOD) δ (ppm) 7.84, 7.74 
(d, 2H, J
ortho
 = 8.5 Hz, H-2′ and H-6′)*, 6.99, 6.88 (d, 2H, J
ortho
 = 8.5 Hz, H-3′ and H-5′)*, 6.42, 6.41 (s, 1H, H-3)*, 6.15 
(s, 1H, H-6), 4.96, 4.89 (d, 1H, J
1″-2″
 = 9.9 Hz, H-1″)*, 4.04 (t, 1H, J
2
″
-1″∼2″-3″
 = 9.6 Hz, H-2″), 3.84 (t, 1H, J
6″a-6″b
 = 11.8 Hz, 
H-6″a), 3.74–3.68 (m, 5H, H-6″b and NCH
2
CH
2
S), 3.61 (t, 1H, J
4″-3″∼4″-5″
 = 9.4 Hz, H-4″), 3.44 (t, 1H, J
3″-2″∼3″-4″
 = 8.9 Hz, 
H-3″), 3.40–3.35 (m, 1H, H-5″), 2.59–2.57 (m, 4H, NCH
2
CH
2
S). 13C NMR (MeOD) δ (ppm) 182.6 (C-4), 165.2 (C-2), 
163.3 (C-7), 161.2 (C-5), 156.8 (C-8a), 152.5 (C-4′), 128.4 (C-2′ and C-6′), 119.5 (C-1′), 114.2 (C-3′ and C-5′), 103.4, 
103.3 (C-8, C-4a), 101.2 (C-3), 98.0 (C-6), 81.4 (C-5″), 78.9 (C-3″), 73.9 (C-1″), 71.5 (C-2″), 70.9 (C-4″), 61.6 (C-6″), 
50.1 (NCH
2
CH
2
S), 25.3 (NCH
2
CH
2
S). *Two peaks were observed due to the presence of rotamers. HRMS-ESI 
(m/z): [M + H]+ calcd for C
25
H
28
NO
9
S 518.1479, found 518.1478; [M + Na]+ calcd for C
25
H
27
NNaO
9
S 540.1299, found 
540.1298.
5,7-Dihydroxy-8-(β-d-glucopyranosyl)-4′-(piperidin-1-yl)flavone (23): Purified by preparative HPLC fol-
lowed by SFCMS (naphthyl column). Reaction yield over two steps: 92 %; LCMS: r.t. = 0.76 min, m/z = 500.2 
[M + H]+ (high pH method); physical appearance: yellow solid; m.p. = 203.0–204.5 °C; 20[ ] 14
D
α = + ° (c 0.2 MeOH); 
1H NMR (MeOD) δ (ppm) 7.93, 7.85 (d, 2H, J
ortho
 = 8.0 Hz, H-2′ and H-6′)*, 7.01 (d, 2H, J
ortho
 = 8.8 Hz, H-3′ and 
H-5′), 6.52 (s, 1H, H-3), 6.26 (s, 1H, H-6), 5.02 (d, 1H, J
1″-2″
 = 9.8 Hz, H-1″)*, 4.16 (t, 1H, J
2″-1″∼2″-3″
 = 9.2 Hz, H-2″), 3.97 
(br d, 1H, J
6″a-6″b
 = 12.1 Hz, H-6″a), 3.82 (dd, 1H, J
6″b-6″a
 = 12.1 Hz, J
6″b-5″
 = 5.7 Hz, H-6″a), 3.72 (t, 1H, J
4″-3″∼4″-5″
 = 9.2 Hz, 
H-4″), 3.56 (t, 1H, J
3″-2″∼3″-4″
 = 8.8 Hz, H-3″), 3.51–3.47 (m, 1H, H-5″), 3.41–3.38 (m, 4H, NCH
2
CH
2
CH
2
), 1.70 (s, 6H, 
NCH
2
CH
2
CH
2
). 13C NMR (MeOD) δ (ppm) 182.5 (C-4), 165.3 (C-2), 163.7 (C-7), 161.2 (C-5), 156.7 (C-8a), 153.9 (C-4′), 
128.1 (C-2′ and C-6′), 119.1 (C-1′), 114.0 (C-3′ and C-5′), 104.1, 103.8 (C-8 and C-4a), 101.0 (C-3), 98.2 (C-6), 81.5 
(C-5″), 78.9 (C-3″), 73.9 (C-1″), 71.5 (C-2″), 70.9 (C-4″), 61.7 (C-6″), 48.3 (NCH
2
CH
2
CH
2
), 25.2 (NCH
2
CH
2
CH
2
), 24.1 
(NCH
2
CH
2
CH
2
). *Two peaks were observed due to the presence of rotamers. HRMS-ESI (m/z): [M + H]+ calcd for 
C
26
H
30
NO
9
 500.1915, found 500.1914; [M + Na]+ calcd for C
26
H
29
NNaO
9
 522.1753, found 522.1731.
5,7-Dihydroxy-8-(β-d-glucopyranosyl)-4′-(piperazin-1-yl)flavone (24): Purified by filtration through an 
Isolute SCX-2 column (Biotage), followed by preparative HPLC. Reaction yield over two steps: 77 %; LCMS: 
r.t. = 0.47  min, m/z = 501.2 [M + H]+ (high pH method); physical appearance: orange solid; m.p. > 360 °C; 
20[ ] 16
D
α = + ° (c 0.3 MeOH); 1H NMR [(CD
3
)
2
SO] δ (ppm) 8.01, 7.92 (d, 2H, J
ortho
 = 8.5 Hz, H-2′ and H-6′)*, 7.07, 7.01 
(d, 2H, J
ortho
 = 8.9 Hz, H-3′ and H-5′)*, 6.79, 6.76 (s, 1H, H-3)*, 6.26 (s, 1H, H-6), 4.69, 4.61 (d, 1H, J
1″-2″
 = 9.9 Hz, 
H-1″)*, 3.85 (t, 1H, J
2″-1″∼2″-3″
 = 9.2 Hz, H-2″), 3.77 (br d, 1H, J
6″a-6″b
 = 11.7 Hz, H-6″a), 3.56–3.22 (m, 8H, H-3″, H-4″, 
H-5″, H-6″b and NCH
2
CH
2
N), 2.91–2.89 (m, 4H, NCH
2
CH
2
N). 13C NMR [(CD
3
)
2
SO] δ (ppm) 182.4 (C-4), 164.8 (C-2), 
163.6 (C-7), 161.5 (C-5), 157.4 (C-8a), 153.5 (C-4′), 128.8 (C-2′ and C-6′), 121.3 (C-1′), 114.2 (C-3′ and C-5′)*, 105.8 
(C-8), 104.5 (C-4a), 102.2 (C-3), 98.6 (C-6), 82.1 (C-5″), 79.2 (C-3″), 74.2 (C-1″), 71.6 (C-2″), 71.4 (C-4″), 62.0 (C-6″), 
47.8 (NCH
2
CH
2
NH), 45.5 (NCH
2
CH
2
NH). *Two peaks were observed due to the presence of rotamers. HRMS-ESI 
(m/z): [M + H]+ calcd for C
25
H
29
N
2
O
9
 501.1868, found 501.1873; [M + Na]+ calcd for C
25
H
28
N
2
NaO
9
 523.1687, found 
523.1687.
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5,7-Dihydroxy-8-(β-d-glucopyranosyl)-4′-(4-methylpiperazin-1-yl)flavone (25): Purified by preparative 
HPLC. Reaction yield over two steps: 70 %; LCMS: r.t. = 0.71 min, m/z = 515.0 [M + H]+ (high pH method); physi-
cal appearance: yellow solid; m.p. = 213.3–214.7 °C; 20[ ] 13
D
α = + ° (c 0.4 MeOH); 1H NMR [(CD
3
)
2
SO] δ (ppm) 13.25 
(s, 1H, OH-5), 8.09 (d, 2H, J
ortho
 = 8.4 Hz, H-2′ and H-6′), 7.02 (d, 2H, J
ortho
 = 8.6 Hz, H-3′ and H-5′), 6.75 (s, 1H, 
H-3), 6.24 (s, 1H, H-6), 4.98–4.93 (m, 2H, OH), 4.70 (d, 1H, J
1″-2″
 = 9.8  Hz, H-1″), 4.62–4.58 (m, 1H, OH), 3.85 
(t, 1H, J
2″-1″∼2″-3″
 = 9.4 Hz, H-2″), 3.79–3.79 (m, 1H, H-6″a), 3.55–3.50 (m, 1H, H-6″b), 3.41–3.22 (m, 7H, H-3″, H-4″, 
H-5″ and NCH
2
CH
2
NCH
3
), 2.46–2.43 (NCH
2
CH
2
NCH
3
), 2.23 (s, 3H, NCH
3
). 13C NMR [(CD
3
)
2
SO] δ (ppm) 181.3 (C-4), 
163.4 (C-2), 162.5 (C-7), 159.8 (C-5), 155.3 (C-8a), 152.6 (C-4′), 127.7 (C-2′ and C-6′), 118.9 (C-1′), 113.2 (C-3′ and C-5′), 
103.9 (C-8), 103.3 (C-4a), 101.1 (C-3), 99.8 (C-6), 81.3 (C-5″), 78.1 (C-3″), 72.8 (C-1″), 70.3 (C-2″), 70.0 (C-4″), 60.8 
(C-6″), 53.7 (NCH
2
CH
2
NCH
3
), 46.0 (NCH
2
CH
2
NCH
3
), 45.1 (NCH
3
). HRMS-ESI (m/z): [M + H]+ calcd for C
25
H
28
NO
10
 
502.1708, found 502.1700; [M + Na]+ calcd for C
25
H
27
NNaO
10
 524.1527, found 524.1518.
5,7-Dihydroxy-8-(β-d-glucopyranosyl)-4′-[(4-methylpiperazin-1-yl)methyl]flavone (26): Purified by 
preparative HPLC, followed by Isolute SCX-2 column chromatography (Biotage). Reaction yield over two 
steps: 84 %; LCMS: r.t. = 0.53 min, m/z = 529.2 [M + H]+ (high pH method); physical appearance: orange solid; 
m.p. = 191.7–192.8 °C; 20[ ] 18
D
α = + ° (c 0.1 MeOH); 1H NMR [MeOD] δ (ppm) 8.11, 8.01 (d, 2H, J
ortho
 = 8.1 Hz, H-2′ 
and H-6′)*, 7.56 (d, 2H, J
ortho
 = 8.5 Hz, H-3′ and H-5′), 6.75 (s, 1H, H-3), 6.30 (s, 1H, H-6), 5.02 (d, 1H, J
1″-2″
 = 9.9 Hz, 
H-1″), 4.12 (t, 1H, J
2″-1″∼2″-3″
 = 9.6 Hz, H-2″), 4.00–3.94 (m, 1H, H-6″a), 3.85–3.79 (m, 1H, H-6″b), 3.72–3.48 (m, 5H, 
H-3″, H-4″, H-5″ and PhCH
2
N), 2.66–2.51 (NCH
2
CH
2
NCH
3
), 2.35 (s, 3H, NCH
3
). 13C NMR [MeOD] δ (ppm) 182.7 
(C-4), 164.3 (C-2), 164.0 (C-7), 161.3 (C-5), 157.1 (C-8a), 142.0 (C-4′), 130.4 (C-1′), 129.7 (C-3′ and C-5′), 126.7 (C-2′ and 
C-6′), 104.2, 104.2 (C-8, C-4a and C-3), 98.8 (C-6), 81.5 (C-5″), 78.8 (C-3″), 73.9 (C-1″), 71.5 (C-2″), 70.9 (C-4″), 61.8 
(PhCH
2
N), 61.6 (C-6″), 54.3 (NCH
2
CH
2
NCH
3
), 52.0 (NCH
2
CH
2
NCH
3
), 44.4 (NCH
3
). HRMS-ESI (m/z): [M + H]+ calcd 
for C
27
H
33
N
2
O
9
 529.2181, found 529.2184; [M + Na]+ calcd for C
27
H
32
N
2
NaO
9
 551.2000, found 551.1996.
2′-Fluoro-5,7-dihydroxy-8-(β-d-glucopyranosyl)-4′-(morpholin-4-yl)flavone (27): Purified by prepara-
tive HPLC, followed by Isolute SCX-2 column chromatography (Biotage). Reaction yield over two steps: 
90 %; LCMS: r.t. = 0.65  min, m/z = 520.2 [M + H]+ (low pH method); physical appearance: orange solid; 
m.p. 225.1–227.2 °C; 20[ ] 8
D
α = + ° (c 0.1 MeOH); 1H NMR (MeOD) δ (ppm) 8.23, 7.91 (t, 1H, J
ortho∼H-F
 = 8.8  Hz, 
H-6′)*, 6.93 (d, 1H, J
ortho
 = 8.7 Hz, H-5′), 6.80 (d, 1H, J
H-F
 = 16.1 Hz, H-3′), 6.65 (s, 1H, H-3), 6.29 (s, 1H, H-6), 
4.99 (d,  1H, J
1″-2″
 = 9.7  Hz, H-1″), 4.09 (t, 1H, J
2″-1″∼2″-3″
 = 9.3  Hz, H-2″), 3.98–3.79 (m, 6H, H-6″a, H-6″b and 
NCH
2
CH
2
O), 3.60 (t, 1H, J
4″-3″∼4″-5″
 = 9.6 Hz, H-4″), 3.53 (t, 1H, J
3″-2″∼3″-4″
 = 8.5 Hz, H-3″), 3.49–3.44 (m, 1H, H-5″), 
3.39–3.29 (NCH
2
CH
2
O, superimposed with the MeOD peak). 13C NMR (MeOD) δ (ppm) 182.6 (C-4), 163.2 (C-7), 
162.5 (d, J
C-F
 = 250.0 Hz, C-2′), 161.4 (C-5), 160.3 (C-2), 156.6 (C-8a), 155.1 (d, J
C-F
 = 11.1 Hz, C-4′), 129.9 (C-6′), 
109.8 (C-5′), 108.2 (d, J
C-F
 = 10.3 Hz, C-1′), 106.4 (C-3), 104.5 (C-4a), 103.7 (C-8), 100.8 (d, J
C-F
 = 28.5 Hz, C-3′), 
98.0 (C-6), 81.5 (C-5″), 78.8 (C-3″), 73.9 (C-1″), 71.4 (C-2″), 70.6, 70.2 (C-4″)*, 66.1 (NCH
2
CH
2
O), 61.4 (C-6″), 47.0 
(NCH
2
CH
2
O). *Two peaks were observed due to the presence of rotamers. HRMS-ESI (m/z): [M + H]+ calcd 
for C
25
H
27
FNO
10
 520.1614, found 520.1613; [M + Na]+ calcd for C
25
H
26
FNNaO
10
 542.1433, found 542.1428.
3′-Fluoro-5,7-dihydroxy-8-(β-d-glucopyranosyl)-4′-(morpholin-4-yl)flavone (28): Purified by prepara-
tive HPLC, followed by Isolute SCX-2 column chromatography (Biotage). Reaction yield over two steps: 76 %; 
LCMS: r.t. = 0.59 min, m/z = 518.0 [M–H]− (high pH method); physical appearance: orange solid; m.p. = 206.0–
207.0 °C; 20[ ] 15
D
α = + ° (c 0.5 MeOH); 1H NMR (MeOD) δ (ppm) 7.88–7.69 (m, 2H, H-2′ and H-6′)*, 7.12 (t, 1H, 
J
ortho∼H-F
 = 8.7 Hz, 1H, H-5′), 6.65 (s, 1H, H-3), 6.28 (s, 1H, H-6), 5.06, 5.01 (d, 1H, J
1″-2″
 = 9.9 Hz, H-1″)*, 4.09 (t, 1H, 
J
2″-1″∼2″-3″
 = 9.6 Hz, H-2″), 4.01 (br d, 1H, J
6″a-6″b
 = 12.4 Hz, H-6″a), 3.89–3.82 (m, 5H, H-6″b and NCH
2
CH
2
O), 3.71 (t, 
1H, J
4″-3″∼4″-5″
 = 9.2 Hz, H-4″), 3.56 (t, 1H, J
3″-2″∼3″-4″
 = 8.6 Hz, H-3″), 3.53–3.49 (m, 1H, H-5″), 3.28–3.19 (m, 4H, NCH-
2
CH
2
O). 13C NMR (MeOD) δ (ppm) 182.6 (C-4), 163.3 (C-7 and C-2), 161.3 (C-5), 156.6 (C-8a), 154.0 (d, J
C-F
 = 245.7 Hz, 
C-3′), 143.0 (d, J
C-F
 = 8.2 Hz, C-4′), 124.5 (d, J
C-F
 = 7.8 Hz, C-1′), 123.6 (C-6′), 118.4 (C-5′), 114.2 (d, J
C-F
 = 22.1 Hz, C-2′), 
104.5 (C-4a), 103.8 (C-8), 103.2 (C-3), 98.1 (C-6), 81.6 (C-5″), 78.8 (C-3″), 73.9 (C-1″), 71.5 (C-2″), 71.1 (C-4″), 66.4 
(NCH
2
CH
2
O), 61.8 (C-6″), 50.0 (NCH
2
CH
2
O). 19F NMR (MeOD) δ (ppm) −122.45, −122.62 (dd, J
F-H-5″
 = 14.2  Hz, 
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J
F-H-2″
 = 8.9 Hz). *Two peaks were observed due to the presence of rotamers. HRMS-ESI (m/z): [M + H]+ calcd for 
C
25
H
27
FNO
10
 520.1614, found 520.1615; [M + Na]+ calcd for C
25
H
26
FNNaO
10
 542.1433, found 542.1431.
3′-Bromo-5,7-dihydroxy-8-(β-d-glucopyranosyl)-4′-(morpholin-4-yl)flavone (29): Purified by prepara-
tive HPLC, followed by Isolute SCX-2 column chromatography (Biotage). Reaction yield over two steps: 95 %; 
LCMS: r.t. = 0.69 min, m/z = 581.0, 582.0 [M + H]+ (Br isotopes, high pH method); physical appearance: yellow 
solid; m.p. = 181.1–182.2 °C; 20[ ] 11
D
α = + ° (c 0.2 MeOH); 1H NMR (MeOD) δ (ppm) 8.24, 8.17 (s, 1H, H-2′)*, 7.97, 
7.92 (d, 1H, J
ortho
 = 8.6 Hz, H-6′)*, 7.20 (d, 1H, J
ortho
 = 8.5 Hz, H-5′), 6.64 (s, 1H, H-3), 6.26 (s, 1H, H-6), 5.04, 5.01 
(d, 1H, J
1″-2″
 = 9.9 Hz, H-1″)*, 4.13–4.03 (m, 2H, H-2″ and H-6″a), 3.96–3.81 (m, 6H, H-4″, H-6″b and NCH
2
CH
2
O), 
3.60–3.53 (m, 2H, H-3″ and H-5″), 3.17–3.10 (m, 4H, NCH
2
CH
2
O). 13C NMR (MeOD) δ (ppm) 182.4 (C-4), 163.4 
(C-7), 162.7 (C-2), 161.2 (C-5), 156.5 (C-8a), 153.4 (C-4′), 131.4 (C-2′), 127.0 (C-1′), 126.7 (C-6′), 120.8 (C-5′), 118.9 
(C-3′), 104.5 (C-4a), 103.8 (C-8), 103.7 (C-3), 98.3 (C-6), 82.0 (C-5″), 78.9 (C-3″), 73.9 (C-1″), 71.5 (C-2″), 71.4 (C-4″), 
66.6 (NCH
2
CH
2
O), 62.3 (C-6″), 51.5 (NCH
2
CH
2
O). *Two peaks were observed due to the presence of rotamers. 
HRMS-ESI (m/z): [M + H]+ calcd for C
25
H
27
BrNO
10
 580.0813, found 580.0811; [M + Na]+ calcd for C
25
H
26
BrNNaO
10
 
602.0632, found 602.0624.
5,7-Dihydroxy-8-(β-d-glucopyranosyl)-3′-(morpholin-4-yl)flavone (30): Purified by preparative HPLC, 
followed by Isolute SCX-2 column chromatography (Biotage). Reaction yield over two steps: 99 %; LCMS: 
r.t. = 0.56 min, m/z = 502.0 [M + H]+ and m/z = 524.0 [M + Na]+ (high pH method); physical appearance: orange 
solid; m.p. = 188.9–190.1 °C; 20[ ] 11
D
α = + ° (c 0.1 MeOH); 1H NMR (MeOD) δ (ppm) 7.65 (br s, 1H, H-2′), 7.48–7.42 
(m, 2H, H-5′ and H-4′), 7.19 (d, 1H, J
ortho
 = 7.8 Hz, H-6′), 6.73 (s, 1H, H-3), 6.30 (s, 1H, H-6), 5.10, 5.01 (d, 1H, 
J
1″-2″
 = 9.9 Hz, H-1″)*, 4.22–4.17, 4.10–4.04 (m, 1H, H-2″)*, 3.98–3.88 (m, 5H, H-6″a and NCH
2
CH
2
O), 3.81–3.74 (m, 
1H, H-6″b), 3.62–3.46 (m, 3H, H-3″, H-4″ and H-5″), 3.29, 3.25 (s, 4H, NCH
2
CH
2
O)*. 13C NMR (MeOD) δ (ppm) 
182.7 (C-4), 165.6 (C-2), 163.7 (C-7), 161.4 (C-5), 157.8 (C-8a), 152.2 (C-3′), 132.3 (C-1′), 129.5 (C-5′), 118.9 (C-6′), 113.3 
(C-4′ and C-2′), 104.6 (C-4a and C-3), 99.7 (C-8), 98.2 (C-6), 81.6 (C-5″), 78.9 (C-3″), 73.8 (C-1″), 71.5 (C-2″), 71.2 
(C-4″), 66.6 (NCH
2
CH
2
O), 61.9, 61.1 (C-6″)*, 49.2, 48.9 (NCH
2
CH
2
O)*. *Two peaks were observed due to the pres-
ence of rotamers. HRMS-ESI (m/z): [M + H]+ calcd for C
25
H
28
NO
10
 502.1708, found 502.1709; [M + Na]+ calcd for 
C
25
H
27
NNaO
10
 524.1527, found 524.1530.
5,7-Dihydroxy-8-(β-d-glucopyranosyl)-4′-dimethylaminoflavone (31): Purified by preparative HPLC, 
followed by Isolute SCX-2 column chromatography (Biotage). Reaction yield over two steps: 91 %; LCMS: 
r.t. = 0.66  min, m/z = 460.2 [M + H]+ (high pH method); physical appearance: orange solid; m.p. = 204.8–
205.7 °C; 20[ ] 16
D
α = + ° (c 0.5 MeOH); 1H NMR (MeOD) δ (ppm) 7.94, 7.84 (d, 2H, J
ortho
 = 8.4 Hz, H-2′ and H-6′)*, 
6.81 (d, 2H, J
ortho
 = 8.7  Hz, H-3′ and H-5′), 6.50 (s, 1H, H-3), 6.26 (s, 1H, H-6), 5.08, 5.01 (d, 1H, J
1″-2″
 = 9.6  Hz, 
H-1″)*, 4.18 (t, 1H, J
2″-1″∼2″-3″
 = 9.6 Hz, H-2″), 3.99, 3.94 (d, 1H, J
6″a-6″b
 = 12.3 Hz, H-6″a)*, 3.82 (dd, 1H, J
6″b-6″a
 = 12.2 Hz, 
J
6″b-5″
 = 6.1 Hz, H-6″b), 3.73 (t, 1H, J
4″-3″∼4″-5″
 = 9.4 Hz, H-4″), 3.57 (t, 1H, J
3″-2″∼3″-4″
 = 9.1 Hz, H-3″), 3.52–3.47 (m, 1H, 
H-5″), 3.01 [s, 6H, N(CH
3
)
2
]. 13C NMR (MeOD) δ (ppm) 182.4 (C-4), 165.8 (C-2), 163.1 (C-7), 161.2 (C-5), 156.6 (C-8a), 
153.0 (C-4′), 128.1 (C-2′ and C-6′), 117.4 (C-1′), 111.3 (C-3′ and C-5′), 103.8 (C-4a), 103.7 (C-8), 100.4 (C-3), 97.9 (C-6), 
81.5 (C-5″), 73.9 (C-3″), 73.8 (C-1″), 71.5 (C-2″), 71.0 (C-4″), 61.8 (C-6″), 38.7 [N(CH
3
)
2
]. *Two peaks were observed 
due to the presence of rotamers. HRMS-ESI (m/z): [M + H]+ calcd for C
23
H
26
NO
9
 460.1602, found 460.1605; 
[M + Na]+ calcd for C
23
H
25
NNaO
9
 482.1422, found 482.1422.
5,7-Dihydroxy-8-(β-d-glucopyranosyl)-4′-(diphenylamino)flavone (32): Purified by preparative HPLC, 
followed by Isolute SCX-2 column chromatography (Biotage). Reaction yield over two steps: 85 %; LCMS: 
r.t. = 0.99 min, m/z = 584.2 [M + H]+ (high pH method); physical appearance: yellow solid; m.p. = 155.5–157.2 °C; 
20[ ] 14
D
α = + ° (c 0.8 MeOH); 1H NMR (MeOD) δ (ppm) 7.95–7.86 (d, 2H, J
ortho
 = 8.8 Hz, H-2′ and H-6′)*, 7.40–7.35 
(m, 4H, N-Ph
2
), 7.19–7.15 (m, 6H, N-Ph
2
), 7.06 (d, 2H, J
ortho
 = 8.8 Hz, H-3′ and H-5′), 6.61 (s, 1H, H-3), 6.30 (s, 1H, 
H-6), 5.05, 4.98 (d, 1H, J
1″-2″
 = 9.9 Hz, H-1″)*, 4.13 (t, 1H, J
2″-1″∼2″-3″
 = 9.3 Hz, H-2″), 3.89, 3.83 (d, 1H, J
6″a-6″b
 = 12.1 Hz, 
H-6″a)*, 3.78–3.41 (m, 4H, H-3″, H-4″, H-5″ and H-6″b)*. 13C NMR (MeOD) δ (ppm) 182.6 (C-4), 164.7 (C-2), 
163.2 (C-7), 161.3 (C-5), 156.7 (C-8a), 151.5 (C-4′), 146.7 (C
q
-Ph), 129.4 (CH-Ph), 127.9 (C-2′ and C-6′), 125.8, 125.7 
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(CH-Ph), 124.5 (C-1′), 120.1 (C-3′ and C-5′), 104.5 (C-4a), 103.8 (C-8), 102.3 (C-3), 98.0 (C-6), 81.5, 81.4 (C-5″)*, 78.7 
(C-3″), 73.9 (C-1″), 71.4 (C-2″), 70.8, 70.7 (C-4″)*, 61.5, 60.8 (C-6″)*. *Two peaks were observed due to the pres-
ence of rotamers. HRMS-ESI (m/z): [M + H]+ calcd for C
33
H
30
NO
9
 584.1915, found 584.1912; [M + Na]+ calcd for 
C
33
H
30
NNaO
9
 606.1735, found 606.1730.
Synthesis of 1-[2,4-bis(ethoxymethoxy)-6-hydroxyphenyl]ethan-1-one (33): 2,4,6-trihydroxyacetophe-
none (4, 3 g, 16.12 mmol) was dissolved in dry acetone (60 mL), after which anhydrous potassium carbonate 
(4.90 g, 35.45 mmol, 2.2 eq.) was added at room temperature. The mixture was stirred at room temperature for 
5 min, and then methyl ethoxymethyl chloride (EOMCl, 3.30 mL, 2.2 eq.) was added in a dropwise manner. 
The mixture was stirred under reflux for the next 4 h and followed by LCMS. After complete disappearance 
of the starting material (91 % reaction yield), the reaction mixture was allowed to cool down to room tem-
perature and the solvent was evaporated. Then, the residue was resuspended in EtOAc, washed with brine 
and extracted with EtOAc (3 × 50 mL). The organic layers were combined, dried over MgSO
4
, filtered and con-
centrated under vacuum. The residue was purified by column chromatography (0:1→1:0 iso-hexane/ethyl 
acetate), affording compound 33 as a colorless solid; m.p. = 47.2–49.2 °C. LCMS: r.t. = 1.26  min, m/z = 285.2 
[M + H]+, 307.2 [M + Na]+, 323.2 [M + K]+ (high pH method). 1H NMR (CDCl
3
) δ (ppm) 13.66 (s, 1H, OH-6), 6.19 
(d, 1H, J
meta
 = 2.4 Hz, H-3), 6.18 (d, 1H, J
meta
 = 2.4 Hz, H-5), 5.21 (s, 2H, OCH
2
O), 5.13 (s, 2H, OCH
2
O), 3.70–3.60 
(m, 4H, OCH
2
CH
3
), 2.55 (s, 3H, CH
3
-Ac), 1.21–1.10 (m, 6H, OCH
2
CH
3
). 13C NMR (CDCl
3
) δ (ppm) 202.2 (C=O), 165.8 
(C-6), 162.6 (C-4), 159.5 (C-2), 105.8 (C-1), 96.0 (C-5), 93.1 (C-3), 92.2, 91.7 (OCH
2
O), 64.0, 63.8 (OCH
2
CH
3
), 32.0 
(CH
3
-Ac), 14.0 (OCH
2
CH
3
). HRMS-ESI (m/z): [M + H]+ calcd for C
14
H
21
O
6
 285.2333, found 285.1324; [M + Na]+ calcd 
for C
14
H
20
NaO
6
 307.1152, found 307.1149.
General procedure for the synthesis of non-glycosylated EOM-protected chalcones
Compound 33 was dissolved in 1,4-dioxane (1.055  mmol in 4  mL) and the appropriate benzaldehyde 
(1.583 mmol, 1.5 eq.) was added. The mixture was stirred until fully homogenized. Then, an aqueous solution 
of NaOH 50 % (w/v, 4 mL) was slowly added and the mixture was stirred at room temperature for 3 h–24 h. All 
reactions were followed by LCMS; once the starting material was fully consumed, the reaction was quenched 
using HCl 2 M, washed with brine and extracted with EtOAc (3 × 10 mL). The organic layers were combined, 
dried over MgSO
4
, filtered and concentrated under vacuum. The residue was purified using the most ade-
quate purification method(s) to afford compounds 34–46.
(2E)-1-[2,4-bis(ethoxymethoxy)-6-hydroxy]phenyl-3-[4-(morpholin-4-yl)phenyl]prop-2-en-1-one 
(34): Purified by preparative HPLC. Reaction yield: 76 %; LCMS: r.t. 1.42 min, m/z = 458.2 [M + H]+ (high pH 
method); physical appearance: yellow solid; m.p. = 206.2–208.3 °C; 1H NMR (CDCl
3
) δ (ppm) 13.98 (s, 1H, 
OH-6′), 7.76 (part A of AB system, 1H, J
trans
 = 15.5 Hz, H-2), 7.70 (part B of AB system, 1H, J
trans
 = 15.5 Hz, H-3), 
7.46 (d, 2H, J
ortho
 = 8.8 Hz, H-2″ and H-6″), 6.82 (d, 2H, J
ortho
 = 8.9 Hz, H-3″ and H-5″), 6.24 (d, 1H, J
meta
 = 2.3 Hz, 
H-5′), 6.18 (d, 1H, J
meta
 = 2.3 Hz, H-3′), 5.25 (s, 2H, OCH
2
O), 5.16 (s, 2H, OCH
2
O), 3.79 (t, J = 5.0 Hz, 4H, NCH
2
CH
2
O), 
3.73–3.63 (m, 4H, OCH
2
CH
3
), 3.19 (t, J = 5.0 Hz, 4H, NCH
2
CH
2
O), 1.19–1.14 (m, 6H, OCH
2
CH
3
). 13C NMR (CDCl
3
) δ 
(ppm) 191.8 (C-1), 166.3 (C-6′), 162.3 (C-4′), 158.9 (C-2′), 150.5 (C-4″), 142.0 (C-3), 129.0 (C-2″, C-6″), 125.1 (C-1″), 
122.9 (C-2), 113.7 (C-3″, C-5″), 106.5 (C-1′), 96.4 (C-5′), 93.8 (C-3′), 92.9, 91.8, (OCH
2
O), 65.6 (NCH
2
CH
2
O), 64.1, 63.8 
(OCH
2
CH
3
), 47.0 (NCH
2
CH
2
O), 14.1 (OCH
2
CH
3
). HRMS-ESI (m/z): [M + H]+ calcd for C
25
H
32
NO
7
 458.2173, found 
458.2177; [M + Na]+ calcd for C
25
H
31
NNaO
7
 480.1993, found 480.1998.
(2E)-1-[2,4-bis(ethoxymethoxy)-6-hydroxy]phenyl-3-[4-(1,4-thiamorpholin-4-yl)phenyl]prop-2-en-1-
one (35): Purified by preparative HPLC. Reaction yield: 77 %; LCMS: r.t. = 1.52 min, m/z = 474.2 [M + H]+ (high 
pH method); physical appearance: yellow solid; m.p. = 123.3–125.2 °C; 1H NMR (CDCl
3
) δ (ppm) 14.02 (s, 1H, 
OH-6′), 7.75 (part A of AB system, 1H, J
trans
 = 15.5 Hz, H-2), 7.70 (part B of AB system, 1H, J
trans
 = 15.5 Hz, H-3), 7.44 
(d, 2H, J
ortho
 = 8.8 Hz, H-2″ and H-6″), 6.78 (d, 2H, J
ortho
 = 8.9 Hz, H-3″ and H-5″), 6.24 (d, 1H, J
meta
 = 2.3 Hz, H-5′), 
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6.18 (d, 1H, J
meta
 = 2.3 Hz, H-3′), 5.25 (s, 2H, OCH
2
O), 5.16 (s, 2H, OCH
2
O), 3.76–3.63 (m, 6H, OCH
2
CH
3
, NCH
2
CH
2
S), 
2.66–2.63 (m, 4H, NCH
2
CH
2
S), 1.20–1.14 (m, 6H, OCH
2
CH
3
). 13C NMR (CDCl
3
) δ (ppm) 191.7 (C-1), 166.3 (C-6′), 
162.3 (C-4′), 158.9 (C-2′), 150.5 (C-4″), 142.1 (C-3), 129.3 (C-2″, C-6″), 124.7 (C-1″), 122.6 (C-2), 114.3 (C-3″, C-5″), 
106.5 (C-1′), 96.4 (C-5′), 93.8 (C-3′), 92.9, 91.8, (OCH
2
O), 64.2, 63.8 (OCH
2
CH
3
), 49.8 (NCH
2
CH
2
S), 25.0 (NCH
2
CH
2
S), 
14.1 (OCH
2
CH
3
). HRMS-ESI (m/z): [M + H]+ calcd for C
25
H
32
NO
6
S 474.1945, found 474.1953; [M + Na]+ calcd for 
C
25
H
31
NNaO
6
S 496.1764, found 496.1770.
(2E)-1-[2,4-bis(ethoxymethoxy)-6-hydroxy]phenyl-3-[4-(piperidine-1-yl)phenyl]prop-2-en-1-one 
(36): Purified by preparative HPLC. Reaction yield: 75 %; LCMS: r.t. = 1.65 min, m/z = 456.2 [M + H]+ (low pH 
method); physical appearance: orange solid; m.p. = 110.4–112.3 °C; 1H NMR (CDCl
3
) δ (ppm) 14.09 (s, 1H, 
OH-6′), 7.73 (s, 2H, H-2 and H-3), 7.42 (d, 2H, J
ortho
 = 8.9 Hz, H-2″ and H-6″), 6.81 (d, 2H, J
ortho
 = 8.9 Hz, H-3″ and 
H-5″), 6.24 (d, 1H, J
meta
 = 2.3 Hz, H-5′), 6.18 (d, 1H, J
meta
 = 2.3 Hz, H-3′), 5.25 (s, 2H, OCH
2
O), 5.16 (s, 2H, OCH
2
O), 
3.71 (q, 2H, J = 7.1 Hz, OCH
2
CH
3
), 3.65 (q, 2H, J = 7.1 Hz, OCH
2
CH
3
), 3.25–3.22 (m, 4H, NCH
2
), 1.62–1.56 (m, 6H, 
NCH
2
CH
2
CH
2
), 1.20–1.14 (m, 6H, OCH
2
CH
3
). 13C NMR (CDCl
3
) δ (ppm) 191.7 (C-1), 166.2 (C-6′), 162.2 (C-4′), 158.9 
(C-2′), 152.0 (C-4″), 142.0 (C-3), 129.2 (C-2″, C-6″), 124.0 (C-1″), 121.9 (C-2), 113.8 (C-3″, C-5″), 106.6 (C-1′), 96.4 
(C-5′), 93.8 (C-3′), 92.9, 91.8, (OCH
2
O), 64.2, 63.7 (OCH
2
CH
3
), 48.1 (NCH
2
), 24.4 (NCH
2
CH
2
), 23.3 (NCH
2
CH
2
CH
2
), 
14.1 (OCH
2
CH
3
). HRMS-ESI (m/z): [M + H]+ calcd for C
26
H
34
NO
6
 456.2381, found 456.2387; [M + Na]+ calcd for 
C
26
H
33
NNaO
6
 478.2200, found 478.2204.
(2E)-1-[2,4-bis(ethoxymethoxy)-6-hydroxy]phenyl-3-[4-(4-tert-butoxycarbonylpiperazin-1-yl)phenyl]
prop-2-en-1-one (37): Purified by column chromatography (cyclohexane/THF 1:0 → 3:2). Reaction yield: 
62 %; LCMS: r.t. = 1.59 min, m/z = 557.2 [M + H]+ and m/z = 579.2 [M + Na]+ (low pH method); physical appear-
ance: orange oil. 1H NMR (CDCl
3
) δ (ppm) 14.04 (s, 1H, OH-6′), 7.83 (part A of AB system, 1H, J
trans
 = 15.5 Hz, 
H-2), 7.77 (part B of AB system, 1H, J
trans
 = 15.5 Hz, H-3), 7.53 (d, 2H, J
ortho
 = 8.8 Hz, H-2″ and H-6″), 6.90 (d, 2H, 
J
ortho
 = 8.9 Hz, H-3″ and H-5″), 6.31 (d, 1H, J
meta
 = 2.3 Hz, H-5′), 6.25 (d, 1H, J
meta
 = 2.3 Hz, H-3′), 5.33 (s, 2H, OCH
2
O), 
5.23 (s, 2H, OCH
2
O), 3.80–3.70 (m, 4H, OCH
2
CH
3
), 3.59 (t, J = 5.0 Hz, 4H, NCH
2
-2 and NCH
2
-6) 3.28 (t, J = 5.0 Hz, 
4H, NCH
2
-3 and NCH
2
-5), 1.49 [s, 9H, C(CH
3
)
3
], 1.27–1.22 (m, 6H, OCH
2
CH
3
). 13C NMR (CDCl
3
) δ (ppm) 192.8 (C-1), 
167.3 (C-6′), 163.2 (C-4′), 159.9 (C-2′), 154.7 (Boc-C=O), 152.3 (C-4″), 143.0 (C-3), 130.1 (C-2″, C-6″), 126.5 (C-1″), 
124.0 (C-2), 115.3 (C-3″, C-5″), 107.6 (C-1′), 97.5 (C-5′), 94.8 (C-3′), 93.9, 92.8, (OCH
2
O), 80.1 (C(CH
3
)
3
), 65.2, 64.8 
(OCH
2
CH
3
), 48.0, 43.2 (NCH
2
), 28.4 [C(CH
3
)
3
], 15.1 (OCH
2
CH
3
). HRMS-ESI (m/z): [M + H]+ calcd for C
30
H
41
N
2
O
8
 
557.2857, found 557.2859; [M + Na]+ calcd for C
30
H
40
N
2
NaO
8
 579.2677, found 579.2679.
(2E)-1-[2,4-bis(ethoxymethoxy)-6-hydroxy]phenyl-3-[4-(4-methylpiperazin-1-yl)phenyl]prop-2-en-1-
one (38): Purified by precipitation in cold methanol, followed by filtration under reduced pressure. Reac-
tion yield: 83 %; LCMS: r.t. = 1.39 min, m/z = 471.2 [M + H]+ (high pH method); physical appearance: orange 
solid; m.p. = 122.6–123.2 °C; 1H NMR (CDCl
3
) δ (ppm) 14.07 (s, 1H, OH-6′), 7.84, 7.80(2) (part A of AB system, 
1H, J
trans
 = 15.5 Hz, H-2), 7.79(6), 7.76 (part B of AB system, 1H, J
trans
 = 15.5 Hz, H-3), 7.52 (d, 2H, J
ortho
 = 8.8 Hz, H-2″ 
and H-6″), 6.90 (d, 2H, J
ortho
 = 8.9 Hz, H-3″ and H-5″), 6.31 (d, 1H, J
meta
 = 2.3 Hz, H-5′), 6.25 (d, 1H, J
meta
 = 2.3 Hz, 
H-3′), 5.32 (s, 2H, OCH
2
O), 5.23 (s, 2H, OCH
2
O), 3.81–3.70 (m, 4H, OCH
2
CH
3
), 3.33 (t, J = 5.0 Hz, 4H, NCH
2
-2 and 
NCH
2
-6) 2.57 (t, J = 5.0 Hz, 4H, NCH
2
-3 and NCH
2
-5), 2.36 (s, 3H, N-CH
3
), 1.27–1.21 (m, 6H, OCH
2
CH
3
). 13C NMR 
(CDCl
3
) δ (ppm) 192.8 (C-1), 167.3 (C-6′), 163.3 (C-4′), 159.9 (C-2′), 152.5 (C-4″), 143.2 (C-3), 130.1 (C-2″, C-6″), 125.9 
(C-1″), 123.6 (C-2), 114.9 (C-3″, C-5″), 107.6 (C-1′), 97.5 (C-5′), 94.8 (C-3′), 93.9, 92.8, (OCH
2
O), 65.2, 64.8 (OCH
2
CH
3
), 
54.8, 47.8 (NCH
2
), 46.2 (NCH
3
), 15.1 (OCH
2
CH
3
). HRMS-ESI (m/z): [M + H]+ calcd for C
26
H
35
N
2
O
6
 471.2490, found 
471.2496; [M + Na]+ calcd for C
26
H
34
N
2
NaO
6
 493.2309, found 493.2309.
(2E)-1-[2,4-bis(ethoxymethoxy)-6-hydroxy]phenyl-3-[4-(4-methylpiperazin-1-yl)methylphenyl]prop-
2-en-1-one (39): Purified by preparative HPLC. Reaction yield: 99 %; LCMS: r.t. = 1.35  min, m/z = 485.2 
[M + H]+ (high pH method); physical appearance: yellow oil; 1H NMR [(CD
3
)
2
CO] δ (ppm) 8.29 (s, 1H, OH-6′), 
8.07, 8.03 (part A of AB system, 1H, J
trans
 = 15.5 Hz, H-2), 7.80, 7.76 (part B of AB system, 1H, J
trans
 = 15.5 Hz, H-3), 
7.69 (d, 2H, J
ortho
 = 8.8 Hz, H-2″ and H-6″), 7.44 (d, 2H, J
ortho
 = 8.9 Hz, H-3″ and H-5″), 6.35 (d, 1H, J
meta
 = 1.8 Hz, 
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H-3′), 6.27 (d, 1H, J
meta
 = 1.8 Hz, H-5′), 5.47 (s, 2H, OCH
2
O), 5.31 (s, 2H, OCH
2
O), 3.82 (q, 4H, J = 7.1 Hz, OCH
2
CH
3
), 
3.73 (q, 4H, J = 7.2  Hz, OCH
2
CH
3
), 3.58 (s, 2H, PhCH
2
N), 2.72 (br s, 4H, NCH
2
-2 and NCH
2
-6), 2.57 (br s, 4H, 
NCH
2
-3 and NCH
2
-5), 1.22–1.17 (m, 6H, OCH
2
CH
3
). 13C NMR [(CD
3
)
2
CO] δ (ppm) 192.8 (C-1), 167.1 (C-6′), 163.9 
(C-4′), 160.3 (C-2′), 142.1 (C-3), 141.1 (C-4″), 134.4 (C-1″), 129.5 (C-3″, C-5″), 128.4 (C-2″, C-6″), 127.1 (C-2), 107.1 (C-1′), 
96.8 (C-5′), 94.8 (C-3′), 94.1, 92.8, (OCH
2
O), 65.0, 64.4 (OCH
2
CH
3
), 61.7 (PhCH
2
N), 54.0, 51.6 (NCH
2
), 44.0 (NCH
3
), 
14.6 (OCH
2
CH
3
). HRMS-ESI (m/z): [M + H]+ calcd for C
27
H
37
N
2
O
6
 485.2646, found 485.2651; [M + Na]+ calcd for 
C
27
H
36
N
2
NaO
6
 507.2466, found 507.2469.
(2E)-1-[2,4-bis(ethoxymethoxy)-6-hydroxy]phenyl-3-[2-fluoro-4-(morpholin-4-yl)phenyl]prop-2-en-1-
one (40): Purified by column chromatography (cyclohexane/acetone 1:0 → 4:1) followed by precipitation in 
cold methanol and filtration under reduced pressure. Reaction yield: 73 %; LCMS: r.t. = 1.45 min, m/z = 476.2 
[M + H]+ (high pH method); physical appearance: yellow solid; m.p. = 111.0–111.9 °C; 1H NMR (CDCl
3
) δ (ppm) 
13.95 (s, 1H, OH-6′), 7.89, 7.85 (part A of AB system, 1H, J
trans
 = 16.4 Hz, H-2), 7.77, 7.73 (part B of AB system, 1H, 
J
trans
 = 16.2 Hz, H-3), 7.39 (t, 1H, J
ortho∼H-F
 = 8.8 Hz, H-6″), 6.59 (dd, 1H, J
ortho
 = 8.8 Hz, J
meta
 = 2.3 Hz, H-5″), 6.50 (dd, 
1H, J
H-F
 = 14.5 Hz, J
meta
 = 2.2 Hz, H-3″), 6.24 (d, 1H, J
meta
 = 2.3 Hz, H-5′), 6.21 (d, 1H, J
meta
 = 2.3 Hz, H-3′), 5.25 (s, 2H, 
OCH
2
O), 5.16 (s, 2H, OCH
2
O), 3.79 (t, J = 5.0 Hz, 4H, NCH
2
CH
2
O), 3.73–3.63 (m, 4H, OCH
2
CH
3
), 3.19 (t, J = 5.0 Hz, 
4H, NCH
2
CH
2
O), 1.19–1.15 (m, 6H, OCH
2
CH
3
). 13C NMR (CDCl
3
) δ (ppm) 191.9 (C-1), 166.3 (C-6′), 162.4 (C-4′), 152.2 
(d, J
C-F
 = 252.8 Hz, C-2″), 159.0 (C-2′), 152.6 (d, J
C-F
 = 11.2 Hz, C-4″), 135.2 (C-3), 130.3 (d, J
C-F
 = 5.6 Hz, C-6″), 125.2 
(C-2), 113.1 (d, J
C-F
 = 12.1 Hz, C-1″), 109.0 (d, J
C-F
 = 2.0 Hz, C-5″), 106.6 (C-1′), 100.6 (d, J
C-F
 = 26.2 Hz, C-3″), 96.3 
(C-5′), 93.7 (C-3′), 92.6, 91.6 (OCH
2
O), 65.5 (NCH
2
CH
2
O), 64.1, 63.8 (OCH
2
CH
3
), 46.7 (NCH
2
CH
2
O), 14.0 (OCH
2
CH
3
). 
19F NMR (CDCl
3
) δ (ppm) −111.20 (dd, J
F-H-5″
 = 14.4  Hz, J
F-H-2″
 = 8.7  Hz). HRMS-ESI (m/z): [M + H]+ calcd for 
C
25
H
31
FNO
7
 476.2079, found 476.2085; [M + Na]+ calcd for C
25
H
30
FNNaO
7
 498.1899, found 498.1904.
(2E)-1-[2,4-bis(ethoxymethoxy)-6-hydroxy]phenyl-3-[3-fluoro-4-(morpholin-4-yl)phenyl]prop-
2-en-1-one (41): Purified by column chromatography (cyclohexane/tetrahydrofurane 1:0 → 3:2). Reac-
tion yield: 76 %; LCMS: r.t. = 1.46 min, m/z = 476.2 [M + H]+ (high pH method); physical appearance: yellow 
solid; m.p. = 108.7–110.2 °C; 1H NMR (CDCl
3
) δ (ppm) 13.89 (s, 1H, OH-6′), 7.84, 7.80 (part A of AB system, 1H, 
J
trans
 = 15.6 Hz, H-2), 7.72, 7.68 (part B of AB system, 1H, J
trans
 = 15.6 Hz, H-3), 7.31–7.26 (m, 2H, H-2″ and H-6″), 
6.92 (t, 1H, J
ortho∼H-F
 = 8.3 Hz, H-5″), 6.32 (d, 1H, J
meta
 = 2.3 Hz, H-5′), 6.24 (d, 1H, J
meta
 = 2.3 Hz, H-3′), 5.33 (s, 2H, 
OCH
2
O), 5.24 (s, 2H, OCH
2
O), 3.88 (t, J = 5.0 Hz, 4H, NCH
2
CH
2
O), 3.81–3.69 (m, 4H, OCH
2
CH
3
), 3.17 (t, J = 5.0 Hz, 
4H, NCH
2
CH
2
O), 1.28–1.20 (m, 6H, OCH
2
CH
3
). 13C NMR (CDCl
3
) δ (ppm) 192.6 (C-1), 167.4 (C-6′), 163.7 (C-4′), 159.9 
(C-2′), 155.2 (d, J
C-F
 = 241.6 Hz, C-3″), 141.4 (d, J
C-F
 = 11.2 Hz, C-4″), 141.3 (C.3), 129.9 (d, J
C-F
 = 7.7 Hz, C-1″), 126.2 (C-2), 
125.9 (d, J
C-F
 = 2.7 Hz, C-6″), 118.3 (d, J
C-F
 = 3.5 Hz, C-5″), 115.0 (d, J
C-F
 = 21.6 Hz, C-2″), 107.4 (C-1′), 97.4 (C-5′), 94.8 
(C-3′), 94.0, 92.8 (OCH
2
O), 66.8 (NCH
2
CH
2
O), 65.4, 64.9 (OCH
2
CH
3
), 50.5, 50.4 (NCH
2
CH
2
O), 15.1, 15.0 (OCH
2
CH
3
). 
19F NMR (CDCl
3
) δ (ppm) −123.20 (dd, J
F-H-6″
 = 14.4  Hz, J
F-H-3″
 = 8.6  Hz). HRMS-ESI (m/z): [M + H]+ calcd for 
C
25
H
31
FNO
7
 476.2079, found 476.2081; [M + Na]+ calcd for C
25
H
30
FNNaO
7
 498.1899, found 498.1897.
(2E)-1-[2,4-bis(ethoxymethoxy)-6-hydroxy]phenyl-3-[3-bromo-4-(morpholin-4-yl)]phenyl]prop-2-en-
1-one (42): Purified by preparative HPLC. Reaction yield: 77 %; LCMS: r.t. = 1.54 min, m/z = 536.0, 537.0, 538.0 
[M + H]+ (Br isotopes; high pH method); physical appearance: orange solid; m.p. = 112.0–112.8 °C; 1H NMR 
(CDCl
3
) δ (ppm) 13.82 (s, 1H, OH-6′), 7.86–7.83 (m, 2H, H-2, part A of AB system, and H-2″), 7.69, 7.65 (part B 
of AB system, 1H, J
trans
 = 15.7 Hz, H-3), 7.49 (dd, 1H, J
ortho
 = 8.3 Hz, J
meta
 = 2.0 Hz, H-6″), 7.04 (d, 1H, J
ortho
 = 8.3 Hz, 
H-5″), 6.32 (d, 1H, J
meta
 = 2.3 Hz, H-5′), 6.25 (d, 1H, J
meta
 = 2.4 Hz, H-3′), 5.34 (s, 2H, OCH
2
O), 5.24 (s, 2H, OCH
2
O), 
3.90 (t, J = 5.0 Hz, 4H, NCH
2
CH
2
O), 3.82–3.70 (m, 4H, OCH
2
CH
3
), 3.11 (t, J = 5.0 Hz, 4H, NCH
2
CH
2
O), 1.29–1.22 
(m, 6H, OCH
2
CH
3
). 13C NMR (CDCl
3
) δ (ppm) 192.5 (C-1), 167.4 (C-6′), 163.8 (C-4′), 160.0 (C-2′), 151.8 (C-4″), 140.5 
(C-3), 133.4 (C-2″), 131.9 (C-1″), 128.9 (C-6″), 127.1 (C-2), 120.7 (C-5″), 119.6 (C-3″), 107.4 (C-1′), 97.4 (C-5′), 94.7 (C-3′), 
93.9, 92.8 (OCH
2
O), 67.0 (NCH
2
CH
2
O), 65.4, 64.9 (OCH
2
CH
3
), 51.8 (NCH
2
CH
2
O), 15.1 (OCH
2
CH
3
). HRMS-ESI (m/z): 
[M + H]+ calcd for C
25
H
31
BrNO
7
 536.1278, found 536.1282; [M + Na]+ calcd for C
25
H
30
BrNNaO
7
 558.1098, found 
558.1102.
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(2E)-1-[2,4-bis(ethoxymethoxy)-6-hydroxy]phenyl-3-[3-(morpholin-4-yl)phenyl]prop-2-en-1-one 
(43): Purified by column chromatography (cyclohexane/tetrahydrofurane 1:0 → 3:2). Reaction yield: 81 %; 
LCMS: r.t. = 1.43 min, m/z = 458.2 [M + H]+ (high pH method); physical appearance: orange oil. 1H NMR (CDCl
3
) 
δ (ppm) 13.84 (s, 1H, OH-6′), 7.93, 7.89 (part A of AB system, 1H, J
trans
 = 15.6 Hz, H-2), 7.76, 7.72 (part B of AB 
system, 1H, J
trans
 = 15.7 Hz, H-3), 7.31 (t, 1H, J
ortho
 = 7.9 Hz, H-5″), 7.16 (br d, 1H, J
ortho
 = 7.7 Hz, H-6″), 7.10 (br s, 1H, 
H-2″), 6.95 (dd, 1H, J
ortho
 = 8.1 Hz, J
meta
 = 2.2 Hz, H-4″), 6.32 (d, 1H, J
meta
 = 2.2 Hz, H-5′), 6.26 (d, 1H, J
meta
 = 2.3 Hz, 
H-3′), 5.32 (s, 2H, OCH
2
O), 5.24 (s, 2H, OCH
2
O), 3.89–3.87 (m, 4H, NCH
2
CH
2
O), 3.79–3.70 (m, 4H, OCH
2
CH
3
), 
3.21–3.18 (m, 4H, NCH
2
CH
2
O), 1.23 (t, 6H, J = 7.1 Hz, OCH
2
CH
3
). 13C NMR (CDCl
3
) δ (ppm) 192.9 (C-1), 167.3 (C-6′), 
163.7 (C-4′), 160.0 (C-2′), 151.7 (C-3″), 142.9 (C-3), 136.4 (C-1″), 129.7 (C-5″), 127.5 (C-2), 119.5 (C-6″), 117.6 (C-4″), 
115.9 (C-2″), 107.5 (C-1′), 97.4 (C-5′), 94.8 (C-3′), 94.0, 92.8, (OCH
2
O), 66.9 (NCH
2
CH
2
O), 65.3, 64.8 (OCH
2
CH
3
), 49.2 
(NCH
2
CH
2
O), 15.1 (OCH
2
CH
3
). HRMS-ESI (m/z): [M + H]+ calcd for C
25
H
32
NO
7
 458.2173, found 458.2176; [M + Na]+ 
calcd for C
25
H
31
NNaO
7
 480.1993, found 480.1990.
(2E)-1-[2,4-bis(ethoxymethoxy)-6-hydroxy]phenyl-3-[2-(morpholin-4-yl)phenyl]prop-2-en-1-one 
(44): Purified by preparative HPLC. Reaction yield: 84 %; LCMS: r.t. = 1.46 min, m/z = 458.2 [M + H]+ (high pH 
method); physical appearance: yellow solid; m.p. = 75.9–76.3 °C; 1H NMR (CDCl
3
) δ (ppm) 13.89 (s, 1H, OH-6′), 
8.14, 8.10 (part A of AB system, 1H, J
trans
 = 15.6 Hz, H-3), 7.82, 7.78 (part B of AB system, 1H, J
trans
 = 15.8 Hz, H-2), 
7.55 (dd, 1H, J
ortho
 = 7.6 Hz, J
meta
 = 1.3 Hz, H-6″), 7.30 (td, 1H, J
ortho
 = 8.1 Hz, J
meta
 = 1.5 Hz, H-4″), 7.05–6.99 (m, 2H, 
H-3″ and H-5″), 6.25 (d, 1H, J
meta
 = 2.3 Hz, H-5′), 6.19 (d, 1H, J
meta
 = 2.3 Hz, H-3′), 5.26 (s, 2H, OCH
2
O), 5.16 (s, 2H, 
OCH
2
O), 3.86–3.83 (m, 4H, NCH
2
CH
2
O), 3.72–3.63 (m, 4H, OCH
2
CH
3
), 2.93–2.91 (m, 4H, NCH
2
CH
2
O), 1.16 (t, 6H, 
J = 7.1  Hz, OCH
2
CH
3
). 13C NMR (CDCl
3
) δ (ppm) 192.1 (C-1), 166.4 (C-6′), 162.6 (C-4′), 160.0 (C-2′), 151.7 (C-2″), 
138.6 (C-3), 129.8 (C-4″), 126.8 (C-6″), 126.3 (C-2), 122.1 (C-5″), 117.8 (C-3″), 106.4 (C-1′), 96.4 (C-5′), 93.7 (C-3′), 
92.8, 91.8, (OCH
2
O), 66.2 (NCH
2
CH
2
O), 64.2, 63.8 (OCH
2
CH
3
), 52.2 (NCH
2
CH
2
O), 14.1, 14.0 (OCH
2
CH
3
). HRMS-ESI 
(m/z): [M + H]+ calcd for C
25
H
32
NO
7
 458.2173, found 458.2177; [M + Na]+ calcd for C
25
H
31
NNaO
7
 480.1993, found 
480.1998.
(2E)-1-[2,4-bis(ethoxymethoxy)-6-hydroxy]phenyl-3-(4-dimethylaminophenyl)prop-2-en-1-one 
(45): Purified by preparative HPLC. Reaction yield: 99 %; LCMS: r.t. = 1.48 min, m/z = 416.2 [M + H]+ (high pH 
method); physical appearance: red solid; m.p. = 100.0–100.5 °C; 1H NMR (CDCl
3
) δ (ppm) 14.19 (s, 1H, OH-6′), 
7.85, 7.81 (part A of AB system, 1H, J
trans
 = 15.4 Hz, H-3), 7.80, 7.76 (part B of AB system, 1H, J
trans
 = 15.1 Hz, H-2), 7.51 
(d, 2H, J
ortho
 = 8.8 Hz, H-2″ and H-6″), 6.82 (d, 2H, J
ortho
 = 8.9 Hz, H-3″ and H-5″), 6.31 (d, 1H, J
meta
 = 2.4 Hz, H-5′), 
6.26 (d, 1H, J
meta
 = 2.4 Hz, H-3′), 5.33 (s, 2H, OCH
2
O), 5.23 (s, 2H, OCH
2
O), 3.79 (q, 2H, J = 7.1 Hz, OCH
2
CH
3
), 3.73 
(q, 2H, J = 7.1 Hz, OCH
2
CH
3
), 3.04 [s, 6H, N(CH
3
)
2
], 1.27–1.22 (m, 6H, OCH
2
CH
3
). 13C NMR (CDCl
3
) δ (ppm) 192.7 
(C-1), 167.2 (C-6′), 163.1 (C-4′), 160.0 (C-2′), 151.9 (C-4″), 144.1 (C-3), 130.4 (C-2″, C-6″), 123.3 (C-1″), 122.0 (C-2), 
111.9 (C-3″, C-5″), 107.7 (C-1′), 97.5 (C-5′), 94.8 (C-3′), 93.9, 92.8, (OCH
2
O), 65.2, 64.7 (OCH
2
CH
3
), 40.2 (N(CH
2
)
3
), 
15.1 (OCH
2
CH
3
). HRMS-ESI (m/z): [M + H]+ calcd for C
23
H
30
NO
6
 416.2068, found 416.2074; [M + Na]+ calcd for 
C
23
H
29
NNaO
6
 438.1887, found 438.1892.
(2E)-1-[2,4-bis(ethoxymethoxy-6-hydroxy]phenyl-3-[4-(diphenylamino)phenyl]prop-2-en-1-one 
(46): Purified by precipitation in cold methanol, followed by column chromatography (cyclohexane/acetone 
1:0 → 9:1). Reaction yield: 61 %; LCMS: r.t. = 1.75 min, m/z = 540.2 [M + H]+ (high pH method); physical appear-
ance: orange oil. 1H NMR (CDCl
3
) δ (ppm) 14.04 (s, 1H, OH-6′), 7.86, 7.82 (part A of AB system, 1H, J
trans
 = 15.7 Hz, 
H-2), 7.78, 7.74 (part B of AB system, 1H, J
trans
 = 15.4 Hz, H-3), 7.45 (d, 2H, J
ortho
 = 8.6 Hz, H-2″ and H-6″), 7.32–7.28 
(m, 4H, NPh
2
), 7.15–7.08 (m, 6H, NPh
2
), 7.02 (d, 2H, J
ortho
 = 8.9 Hz, H-3″ and H-5″), 6.31 (d, 1H, J
meta
 = 2.4 Hz, H-3′), 
6.26 (d, 1H, J
meta
 = 2.4 Hz, H-5′), 5.31 (s, 2H, OCH
2
O), 5.23 (s, 2H, OCH
2
O), 3.78–3.69 (m, 4H, OCH
2
CH
3
), 1.23 (t, 6H, 
J = 7.1 Hz, OCH
2
CH
3
). 13C NMR (CDCl
3
) δ (ppm) 192.7 (C-1), 167.4 (C-6′), 163.4 (C-4′), 160.0 (C-2′), 149.9 (C-4″), 146.9 
(C
q
-Ph), 142.7 (C-3), 129.6 (C-2″, C-6″), 129.5 (CH-Ph), 128.5 (C-1″), 125.5, 124.7 (CH-Ph), 124.1 (C-2), 121.7 (C-3″, 
C-5″), 107.5 (C-1′), 97.5 (C-5′), 94.8 (C-3′), 93.9, 92.8, (OCH
2
O), 65.2, 64.8 (OCH
2
CH
3
), 15.1 (OCH
2
CH
3
). HRMS-ESI 
(m/z): [M + H]+ calcd for C
33
H
34
NO
6
 540.2381, found 540.2387; [M + Na]+ calcd for C
33
H
33
NNaO
6
 562.2200, found 
562.2213.
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General procedure for the synthesis of non-glycosylated flavones
Each chalcone 34–46 was dissolved in dry pyridine (0.248  mmol in 7.33  mL). Then, catalytic amounts of 
I
2
 (0.087 mmol, 0.35 eq.) were added and the mixture was stirred under reflux for 24 h–72 h. All reactions 
were followed by LCMS. Once the starting material was fully consumed, the mixture was allowed to reach 
room temperature and the pyridine was co-evaporated with toluene under reduced pressure. The residue 
was resuspended in dichloromethane, washed first with a saturated solution of sodium thiosulfate, and then 
with brine. The flavone was extracted with dichloromethane (3 × 30 mL), dried over MgSO
4
, and the solution 
filtered and concentrated under vacuum. The residue was then resuspended in ethanol (15 mL) and p-TsOH 
(12 % in AcOH, 0.1 mL) was added. The reaction was stirred under reflux for 2 h–24 h. After having reached 
completion by LCMS, the solvent was evaporated under vacuum and the residue purified using the most 
adequate purification method(s) to afford compounds 2 and 47–57.
5,7-Dihydroxy-4′-(morpholin-4-yl)flavone (2): Purified by preparative HPLC. Reaction yield over two 
steps: 68 %; LCMS: r.t. = 1.07  min, m/z = 340.0 [M + H]+ (low pH method); physical appearance: orange 
solid; m.p. = 234.0–235.6 °C. 1H NMR [(CD
3
)OD] δ (ppm) 7.88 (d, 2H, J
ortho
 = 9.0 Hz, H-2′ and H-6′), 7.07 (d, 2H, 
J
ortho
 = 9.1 Hz, H-3′ and H-5′), 6.59 (s, 1H, H-3), 6.46 (d, 1H, J
meta
 = 2.2 Hz, H-8), 6.22 (d, 1H, J
meta
 = 2.1 Hz, H-6), 
3.86–3.84 (m, 4H, NCH
2
CH
2
O), 3.35–3.35 (NCH
2
CH
2
O, overlapped with metanol-d
4
 peak). 13C NMR [(CD
3
)OD] 
δ (ppm) 183.9 (C-4), 166.2 (C-7), 163.5 (C-5), 159.6 (C-8a), 155.5 (C-4′), 129.1 (C-2′, C-6′), 122.0 (C-1′), 115.6 (C-3′, 
C-5′), 103.5 (C-4a), 100.3 (C-6), 95.2 (C-8), 67.7 (NCH
2
CH
2
O), 49.2 (NCH
2
CH
2
O). HRMS-ESI (m/z): [M + H]+ calcd 
for C
19
H
18
NO
5
 340.1179, found 340.1175.
5,7-Dihydroxy-4′-(1,4-thiamorpholin-4-yl)flavone (47): Purified by preparative HPLC, followed by Isolute 
SCX-2 column chromatography (Biotage). Reaction yield over two steps: 99 %; LCMS: r.t. = 1.04 min, m/z = 356.0 
[M + H]+ (high pH method); physical appearance: yellow solid; m.p. = 245.4–247.3 °C; 1H NMR [(CD
3
)
2
CO] 
δ (ppm) 12.98 (s, 1H, OH-5), 7.76 (d, 2H, J
ortho
 = 8.7 Hz, H-2′ and H-6′), 6.92 (d, 2H, J
ortho
 = 9.2 Hz, H-3′ and H-5′), 
6.45 (s, 1H, H-3), 6.39 (d, 1H, J
meta
 = 2.2 Hz, H-8), 6.11 (d, 1H, J
meta
 = 2.1 Hz, H-6), 3.72–3.69 (m, 4H, NCH
2
CH
2
O), 
2.58–2.56 (m, 4H, NCH
2
CH
2
O). 13C NMR [(CD
3
)
2
CO] δ (ppm) 182.1 (C-4), 164.3 (C-2), 163.9 (C-7), 162.5 (C-5), 157.9 
(C-8a), 152.3 (C-4′), 128.0 (C-2′ and C-6′), 119.4 (C-1′), 114.5 (C-3′ and C-5′), 104.5 (C-4a), 102.2 (C-3), 98.7 (C-6), 
93.8 (C-8), 50.2 (NCH
2
CH
2
O), 47.4 (NCH
2
CH
2
O). HRMS-ESI (m/z): [M + H]+ calcd for C
19
H
18
NO
4
S 356.0951, found 
356.0949; [M + Na]+ calcd for C
19
H
17
NNaO
4
S 378.0770, found 378.0767.
5,7-Dihydroxy-4′-(piperidin-1-yl)flavone (48): Purified by preparative HPLC. Reaction yield over two 
steps: 65 %; LCMS: r.t. = 1.26 min, m/z = 338.0 [M + H]+ (low pH method); physical appearance: golden solid; 
m.p. = 233.2–234.4 °C; 1H NMR [CO(CD
3
)
2
] δ (ppm) 13.14 (s, 1H, OH-5), 7.87 (d, 2H, J
ortho
 = 8.7 Hz, H-2′ and H-6′), 
7.04 (d, 2H, J
ortho
 = 8.8 Hz, H-3′ and H-5′), 6.57 (s, 1H, H-3), 6.52 (br s, 1H, H-8), 6.24 (br s, 1H, H-6), 3.40 (br s, 4H, 
NCH
2
), 1.66 (br s, 6H, NCH
2
CH
2
CH
2
). 13C NMR [CO(CD
3
)
2
] δ (ppm) 182.0 (C-4), 164.5 (C-2), 163.8 (C-7), 162.5 (C-5), 
157.8 (C-8a), 153.8 (C-4′), 127.7 (C-2′ and C-6′), 118.9 (C-1′), 114.1 (C-3′ and C-5′), 104.4 (C-4a), 101.9 (C-3), 98.7 (C-6), 
93.7 (C-8), 48.2 (NCH
2
), 25.2 (NCH
2
CH
2
CH
2
), 24.2 (NCH
2
CH
2
CH
2
). HRMS-ESI (m/z): [M + H]+ calcd for C
20
H
20
NO
4
 
338.1387, found 338.1385; [M + Na]+ calcd for C
20
H
20
NNaO
4
 360.1206, found 360.1194.
5,7-Dihydroxy-4′-(piperazin-1-yl)flavone (49): Purified by preparative HPLC, followed by Isolute SCX-2 
column chromatography (Biotage). Reaction yield over two steps: 99 %; LCMS: r.t. = 0.65  min, m/z = 339.0 
[M + H]+ (low pH method); physical appearance: orange solid; m.p. >360 °C; 1H NMR [(CD
3
)
2
SO] δ (ppm) 7.94 
(d, 2H, J
ortho
 = 8.8 Hz, H-2′ and H-6′), 7.10 (d, 2H, J
ortho
 = 8.3  Hz, H-3′ and H-5′), 6.81 (s, 1H, H-3), 6.55 (d, 1H, 
J
meta
 = 2.0 Hz, H-8), 6.23 (d, 1H, J
meta
 = 2.0 Hz, H-6), 3.55–3.47 (m, 4H, NCH
2
CH
2
NH), 3.13–3.07 (m, 4H, NCH
2
CH
2
NH). 
13C NMR [(CD
3
)
2
SO] δ (ppm) 182.1 (C-4), 164.8 (C-2), 164.1 (C-7), 161.8 (C-5), 157.7 (C-8a), 153.1 (C-4′), 128.3 (C-2′ 
and C-6′), 120.9 (C-1′), 114.9 (C-3′ and C-5′), 104.1 (C-4a), 102.9 (C-3), 99.4 (C-6), 94.5 (C-8), 45.5 (NCH
2
CH
2
NH), 
45.4 (NCH
2
CH
2
NH). HRMS-ESI (m/z): [M + H]+ calcd for C
19
H
19
N
2
O
4
 339.1339, found 339.1335.
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5,7-Dihydroxy-4′-(4-methylpiperazin-1-yl)flavone (50): Purified by preparative HPLC. Reaction yield over 
two steps: 79 %; LCMS: r.t. = 0.81 min, m/z = 353.0 [M + H]+ (low pH method); physical appearance: orange 
solid; m.p. = 225.8–226.6 °C; 1H NMR [MeOD/CO(CD
3
)
2
 10:1] δ (ppm) 7.77 (d, 2H, J
ortho
 = 8.6 Hz, H-2′ and H-6′), 
6.96 (d, 2H, J
ortho
 = 8.7 Hz, H-3′ and H-5′), 6.47 (s, 1H, H-3), 6.35 (br s, 1H, H-8), 6.09 (br s, 1H, H-6), 3.29–3.27 
(m, 4H, NCH
2
CH
2
NCH
3
), 2.44–2.42 (m, 4H, NCH
2
CH
2
NCH
3
), 2.18 (s, 3H, NCH
3
). 13C NMR [MeOD/CO(CD
3
)
2
 10:1] δ 
(ppm) 182.0 (C-4), 165.2 (C-7), 164.3 (C-2), 162.0 (C-5), 158.0 (C-8a), 153.6 (C-4′), 127.6 (C-2′ and C-6′), 120.0 (C-1′), 
114.3 (C-3′ and C-5′), 103.9 (C-4a), 102.1 (C-3), 99.0 (C-6), 94.0 (C-8), 54.5 (NCH
2
CH
2
NCH
3
), 46.9 (NCH
2
CH
2
NCH
3
), 
45.2 (NCH
3
). HRMS-ESI (m/z): [M + H]+ calcd for C
20
H
21
N
2
O
4
 353.1496, found 353.1495; [M + Na]+ calcd for 
C
20
H
20
N
2
NaO
4
 375.1315, found 375.1312.
5,7-Dihydroxy-4′-[(4-methylpiperazin-1-yl)methyl]flavone (51): Purified by preparative HPLC, followed 
by Isolute SCX-2 column chromatography (Biotage). Reaction yield over two steps: 90 %; LCMS: r.t. = 0.71 min, 
m/z = 367.0 [M + H]+ (low pH method); physical appearance: brownish oil. 1H NMR [CO(CD
3
)
2
] δ (ppm) 7.83 
(d, 2H, J
ortho
 = 8.1 Hz, H-2′ and H-6′), 7.38 (d, 2H, J
ortho
 = 7.9 Hz, H-3′ and H-5′), 6.58 (s, 1H, H-3), 6.41 (br s, 1H, H-8), 
6.13 (br s, 1H, H-6), 3.42 (s, 2H, PhCH
2
N), 3.39–3.21 (m, 8H, NCH
2
CH
2
NCH
3
), 2.07 (s, 3H, NCH
3
). 13C NMR [CO(CD
3
)
2
] 
δ (ppm) 182.1 (C-4), 165.6 (C-7), 163.6 (C-2), 162.2 (C-5), 158.1 (C-8a), 143.2 (C-4′), 130.0 (C-1′), 129.5 (C-3′ and C-5′), 
126.2 (C-2′ and C-6′), 104.8 (C-3), 104.1 (C-4a), 99.3 (C-6), 94.2 (C-8), 62.0 (PhCH
2
N), 54.9 (NCH
2
CH
2
NCH
3
), 52.8 
(NCH
2
CH
2
NCH
3
), 45.3 (NCH
3
). HRMS-ESI (m/z): [M + H]+ calcd for C
21
H
23
N
2
O
4
 367.1652, found 367.1649.
2′-Fluoro-5,7-dihydroxy-4′-(morpholin-4-yl)flavone (52): Purified by preparative HPLC. Reaction yield 
over two steps: 92 %; LCMS: r.t. = 0.89  min, m/z = 358.2 [M + H]+ (high pH method); physical appearance: 
orange solid; m.p. = 243.2–244.0 °C; 1H NMR [(CD
3
)
2
CO] δ (ppm) 12.98 (s, 1H, OH-5), 7.90 (t, 1H, J
ortho∼H-F
 = 9.0 Hz, 
H-6′), 6.95 (d, 1H, J
ortho
 = 8.8 Hz, H-5′), 6.85 (d, 1H, J
H-F
 = 16.0 Hz, H-3′), 6.57 (s, 1H, H-3), 6.52 (br s, 1H, H-8), 
6.27 (br s, 1H, H-6), 3.81–3.79 (m, 4H, NCH
2
CH
2
O), 3.40–3.37 (m, 4H, NCH
2
CH
2
O). 13C NMR [(CD
3
)
2
CO] δ (ppm) 
181.9 (C-4), 164.0 (C-7), 162.2 (d, J
C-F
 = 250.8 Hz, C-2′), 162.1 (C-5), 159.9 (C-2), 157.9 (C-8a), 155.1 (d, J
C-F
 = 11.9 Hz, 
C-4′), 129.6 (d, J
C-F
 = 3.70 Hz, C-6′), 110.0 (d, J
C-F
 = 1.8 Hz, C-5′), 108.1 (d, J
C-F
 = 10.2 Hz, C-1′), 107.2 (d, J
C-F
 = 13.3 Hz, 
C-3), 101.2 (d, J
C-F
 = 27.5  Hz, C-3′), 104.4 (C-4a), 98.7 (C-6), 93.8 (C-8), 66.1 (NCH
2
CH
2
O), 47.1 (NCH
2
CH
2
O). 
19F NMR (CDCl
3
) δ (ppm) −110.42 (dd, J
F-H-5″
 = 15.7  Hz, J
F-H-2″
 = 8.8  Hz). HRMS-ESI (m/z): [M + H]+ calcd for 
C
19
H
17
FNO
5
 358.1085, found 358.1081; [M + Na]+ calcd for C
19
H
16
FNNaO
5
 380.0905, found 380.0903.
3′-Fluoro-5,7-dihydroxy-4′-(morpholin-4-yl)flavone (53): Purified by preparative HPLC. Reaction yield 
over two steps: 93 %; LCMS: r.t. = 1.10  min, m/z = 358.0 [M + H]+ (low pH method); physical appearance: 
orange solid; m.p. = 241.6–242.8 °C; 1H NMR [(CD
3
)
2
CO] δ (ppm) 7.84–7.77 (m, 2H, H-2′ and H-6′), 7.18 (t, 1H, 
J
ortho∼H-F
 = 8.7 Hz, H-5′), 6.72 (s, 1H, H-3), 6.60 (br s, 1H, H-8), 6.27 (br s, 1H, H-6), 3.83–3.81 (m, 4H, NCH
2
CH
2
O), 
3.24–3.22 (m, 4H, NCH
2
CH
2
O). 13C NMR [(CD
3
)
2
CO] δ (ppm) 182.0 (C-4), 164.1 (C-7), 162.6 (d, J
C-F
 = 2.5 Hz, C-2), 
162.2 (C-5), 157.9 (C-8a), 154.8 (d, J
C-F
 = 246.5 Hz, C-3′), 143.0 (d, J
C-F
 = 8.0 Hz, C-4′), 124.4 (d, J
C-F
 = 8.2 Hz, C-1′), 
123.3 (d, J
C-F
 = 2.9  Hz, C-6′), 118.7 (d, J
C-F
 = 3.7  Hz, C-5′), 114.1 (d, J
C-F
 = 24.1  Hz, C-2′), 104.5 (C-4a), 104.2 (C-3), 
98.8 (C-6), 94.0 (C-8), 66.5 (NCH
2
CH
2
O), 50.2 (d, J
C-F
 = 4.4  Hz, NCH
2
CH
2
O). 19F NMR (CDCl
3
) δ (ppm) −122.29 
(dd, J
F-H-6″
 = 14.2 Hz, J
F-H-3″
 = 8.8 Hz). HRMS-ESI (m/z): [M + H]+ calcd for C
19
H
17
FNO
5
 358.1085, found 358.1083; 
[M + Na]+ calcd for C
19
H
16
FNNaO
5
 380.0905, found 380.0900.
3′-Bromo-5,7-dihydroxy-4′-(morpholin-4-yl)flavone (54): Purified by preparative HPLC followed by 
SFC-MS (PPU column). Reaction yield over two steps: 84 %; LCMS: r.t. = 0.96 min, m/z = 417.8, 419.8, 420.8 
[M + H]+ (Br isotopes; high pH method); physical appearance: brownish oil. 1H NMR [(CD
3
)
2
CO] δ (ppm) 12.90 
(s, 1H, OH-7), 8.27 (s, 1H, H-2′), 8.05 (d, 1H, J
ortho
 = 8.6 Hz, H-6′), 7.32 (d, 1H, J
ortho
 = 8.6 Hz, H-5′), 6.77 (s, 1H, H-3), 
6.60 (br s, 1H, H-8), 6.28 (br s, 1H, H-6), 3.85–3.82 (m, 4H, NCH
2
CH
2
O), 3.17–3.15 (m, 4H, NCH
2
CH
2
O). 13C NMR 
[(CD
3
)
2
CO] δ (ppm) 182.0 (C-4), 164.2 (C-7), 163.3 (C-5), 162.2 (C-2), 157.9 (C-8a), 153.5 (C-4′), 131.7 (C-2′), 127.0 
(C-1′), 126.9 (C-6′), 121.1 (C-5′), 118.9 (C-3′), 104.9 (C-4a and C-3), 98.9 (C-6), 94.1 (C-8), 66.5 (NCH
2
CH
2
O), 51.7 
(NCH
2
CH
2
O). HRMS-ESI (m/z): [M + H]+ calcd for C
19
H
17
BrNO
5
 418.0285, found 418.0280; [M + Na]+ calcd for 
C
19
H
16
BrNNaO
5
 440.0104, found 440.0102.
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5,7-Dihydroxy-3′-(morpholin-4-yl)flavone (55): Purified by Isolute SCX-2 column chromatography 
(Biotage) followed by preparative HPLC. Reaction yield over two steps: 85 %; LCMS: r.t. = 1.06 min, m/z = 340.2 
[M + H]+ and m/z = 362.2 [M + Na]+ (low pH method); physical appearance: orange solid; m.p. = 135.1–137.6 °C; 
1H NMR [(CD
3
)
2
CO] δ (ppm) 12.93 (s, 1H, OH-5), 7.60 (s, 1H, H-2′), 7.50–7.42 (m, 2H, H-5′ and H-4′), 7.21 (d, 1H, 
J
ortho
 = 8.1 Hz, H-6′), 6.79 (s, 1H, H-3), 6.57 (br s, 1H, H-8), 6.28 (br s, 1H, H-6), 3.83–3.81 (m, 4H, NCH
2
CH
2
O), 
3.30–3.28 (m, 4H, NCH
2
CH
2
O). 13C NMR [(CD
3
)
2
CO] δ (ppm) 182.2 (C-4), 164.3 (C-2), 164.0 (C-7), 162.2 (C-5), 158.0 
(C-8a), 152.1 (C-3′), 132.2 (C-1′), 129.8 (C-5′), 118.6 (C-6′), 117.2 (C-4′), 112.8 (C-2′), 105.4 (C-4a and C-3), 98.8 (C-6), 
94.1 (C-8), 66.4 (NCH
2
CH
2
O), 48.7 (NCH
2
CH
2
O). HRMS-ESI (m/z): [M + H]+ calcd for C
19
H
18
NO
5
 340.1179, found 
340.1177.
5,7-Dihydroxy-4′-dimethylaminoflavone (56): Purified by preparative HPLC. Reaction yield over two 
steps: 54 %; LCMS: r.t. = 1.12 min, m/z = 298.0 [M + H]+ (low pH method); physical appearance: orange solid; 
m.p. = 291.3–292.7 °C. 1H NMR [(CD
3
)
2
SO] δ (ppm) 13.11 (s, 1H, OH-5), 7.89 (d, 2H, J
ortho
 = 9.0 Hz, H-2′ and H-6′), 
6.81 (d, 2H, J
ortho
 = 9.0 Hz, H-3′ and H-5′), 6.72 (s, 1H, H-3), 6.46 (d, 1H, J
meta
 = 2.1 Hz, H-8), 6.16 (d, 1H, J
meta
 = 2.1 Hz, 
H-6), 3.04 [s, 6H, N(CH
3
)
2
]. 13C NMR [(CD
3
)
2
SO] δ (ppm) 181.9 (C-4), 164.7 (C-2), 164.6 (C-7), 161.9 (C-5), 157.7 
(C-8a), 153.1 (C-4′), 128.3 (C-2′, C-6′), 117.0 (C-1′), 112.1 (C-3′, C-5′), 104.0 (C-4a), 101.7 (C-3), 99.2 (C-6), 94.3 (C-8), 
40.4 [N(CH
3
)
2
]. HRMS-ESI (m/z): [M + H]+ calcd for C
17
H
16
NO
4
 298.1074, found 298.101.
5,7-Dihydroxy-4′-(diphenylamino)flavone (57): Purified by preparative HPLC. Reaction yield over two 
steps: 63 %; LCMS: r.t. = 1.38 min, m/z = 422.0 [M + H]+ (high pH method); physical appearance: dark orange 
oil. 1H NMR [(CD
3
)
2
SO] δ (ppm) 7.86 (d, 2H, J
ortho
 = 8.8 Hz, H-2′ and H-6′), 7.39–7.34 (m, 4H, N-Ph
2
), 7.18–7.15 
(m, 8H, N-Ph
2
, H-3′ and H-5′), 6.89 (s, 1H, H-3), 6.49 (d, 1H, J
meta
 = 2.1 Hz, H-8), 6.19 (d, 1H, J
meta
 = 2.1 Hz, H-6). 
13C NMR [(CD
3
)
2
SO] δ (ppm) 182.1 (C-4), 164.7 (C-7), 164.1 (C-2), 161.8 (C-5), 158.0 (C-8a), 151.4 (C-4′), 146.1 (C
q
-
Ph), 129.3 (CH-Ph), 128.9 (C-2′ and C-6′), 125.3, 125.2 (CH-Ph), 124.1 (C-1′), 122.0 (C-3′ and C-5′), 104.7 (C-4a), 103.8 
(C-3), 99.3 (C-6), 94.9 (C-8). HRMS-ESI (m/z): [M + H]+ calcd for C
27
H
20
NO
4
 422.1387, found 422.1384; [M + Na]+ 
calcd for C
27
H
19
NNaO
4
 444.1206, found 444.1213.
Preparation of Aβo
ADDLs were prepared as described previously [29, 30] with some modifications. Briefly, 16 mg of lyophi-
lized human Aβ1-42 peptide was equilibrated to room temperature for 30 min prior to resuspension in hex-
afluoropropan-2-ol (HFIP) to produce a 4.5 mg/mL Aβ solution. The peptide solution was incubated at room 
temperature for a further 30 min to ensure complete dissolution. The resulting peptide solution was then 
aliquotted into 0.5 mg aliquots in LoBind microcentrifuge tubes, centrifuged at maximum speed for 5 min, 
and dried under N
2
 to remove HFIP for 1 h. The dried peptide films were stored at −20 °C in a desiccator 
jar. Aβ1-42 peptide films were removed from the freezer 10 min prior to use to equilibrate to room tempera-
ture. HiTrap desalting columns (5 mL; GE Healthcare) were carefully equilibrated with 20 mL of Neurobasal 
Medium (Gibco by Life Technologies). Each peptide film was resuspended in 250 µL of DMSO to yield a 
final Aβ concentration of 10 mM and were vortexed and pooled prior to adding to the column. DMSO was 
removed from the peptide by passing the solution through the HiTrap column, and the peptide was eluted 
into two volumes of 1 mL of Neurobasal Medium passed through the column. The eluted peptide was col-
lected into LoBind tubes and protein concentration was assessed via a Bradford Protein Assay kit (Thermo 
Fischer Scientific). Each tube was normalized with Neurobasal Medium to a final concentration of 220 µg/
mL (50 µM) and split equally into LoBind tubes to allow an equal ratio of liquid:air (e.g. 1 mL peptide in a 
2 mL tube). The normalized Aβ1-42 monomers were then oligomerized for 1 h at 25 °C using a plate shaker at 
330 rpm. Finally, the oligomers were centrifuged for 10 min at 14 500 rpm, the supernatant was collected and 
analysed using a DynaPro Dynamic Light Scattering (DLS) Instrument (Wyatt Technology), and the results 
analysed using Dynamics V7 Software. The freshly prepared Aβo were stored at −80 °C until needed for STD 
NMR experiments.
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STD NMR screening assay against Aβo
All samples were prepared in 550 µL of deutered 10 mM phosphate buffer. Aβo and test compounds were 
added to reach final concentrations of 2 and 200 µM, respectively (1:100 molar ratio). The final percentage 
of DMSO was 2 % in screening experiments, and 4 % in the competition assay between compound 51 and 
bexarotene. Controls were prepared in the absence of Aβo, but maintaining the same relative volumes of 
buffer, Neurobasal Medium and DMSO. All experiments were performed on a Bruker Avance III or 600 MHz 
spectrometer equipped with a QCI cryoprobe. For the acquisition, a standard Bruker pulse sequence was 
used, with 2 s of saturation at 0 ppm and −40 ppm for on and off resonance. Double solvent suppression was 
achieved with a DPFGSE element incorporating a selective 180 pulse designed to flip both the water (from 
buffer) and DMSO (from ligand stock) peaks. Typically, 128 scans were acquired prior to processing with a 
1 Hz lien broadening function. Data were processed in topspin using the stdsplit AU program.
Cell culture
Human embryonic kidney (HEK) cells were grown in Dulbecco’s modified essential medium (DMEM; D5796, 
Sigma) supplemented with 10 % fetal bovine serum (FBS; 10695023, Fisher), 1 % penicillin-streptomycin 
(10452882, Fisher) and 4 mM L-glutamine (G7513, Sigma), and maintained at 37 °C in a 5 % CO
2
 atmosphere.
Immunocytochemistry analysis of compound-mediated Aβo-PrPC disruption
Ninety six-well plates were incubated with 50 µL of poly-l-ornithine hydrobromide 100 µg/mL for 40 min and 
washed with PBS 3 times. HEK cells were seeded onto the plates diluted in Phenol red-free DMEM medium 
with high glucose (Gibco) to achieve 2 × 104 cells per 100 µL in each well. The cells were incubated at 37 °C 
with 5 % CO
2
 overnight. Then, the medium was removed and 50 µL of conditioning medium with recombi-
nant Aβo prepared by the Sheffield Institute for Translational Neuroscience (SiTraN) 1000 pc/mL was added 
to each well. These oligomers were derived from Chinese Hamster Ovary cells (7PA2 cells) stably transfected 
with cDNA encoding APP751, an amyloid precursor protein that contains the Val717Phe familial Alzheimer’s 
disease mutation, as previously described by Kittelberger et al. [31]. After a 2 h-long incubation period, the 
conditioning medium was removed and the cells were washed once with PBS. Then, 100 µL of fresh Phenol 
red-free DMEM medium with high glucose were added to each well and the cells were incubated with the 
flavone derivatives at the desired concentration (10 µM in the screening assay or 1 µM–20 µM in the dose-
response experiment with compound 26) in 0.5 % of DMSO for 1 h. The medium was subsequently removed. 
The cells were washed with 100 µL of PBS containing Mg2+ and Ca2+, after which 100 µL of 4 % PFA were 
added to each well. Once incubated for 15  min at room temperature, the PFA was removed and the cells 
were washed once again with 100 µL of PBS containing Mg2+ and Ca2+. One hundred µL of PBS-T with 5 % of 
Donkey serum were added and the cells were incubated for 1 h at room temperature. Then, the blocking solu-
tion was removed and the primary antibody (anti-Aβo 6E10 antibody prepared in 50 µL of PBS-T with 5 % of 
Donkey serum, 1:250 dilution) was added prior to overnight incubation at 4 °C. After removal of the primary 
antibody, the cells were washed 3 times with 50 µL of PBS-T for 5 min at room temperature. Fifty microliter of 
the secondary antibody (Alexa fluor 594 anti-mouse antibody, prepared in PBS-T, 1:500 dilution) were subse-
quently added to each well and the cells were incubated another hour at room temperature. The liquid was 
aspirated and the cells were washed twice with PBS-T and once with PBS (50 µL each wash). Fifty microliter of 
4′,6-diamidino-2-phenylindole (DAPI, 100 ng/mL in PBS) were added to each well. Following 5 min of incuba-
tion, DAPI was removed and the cells washed with 100 µL of PBS 3 times. One hundred microliter of PBS were 
finally added and the imaging was carried out by The Wolfson Light Microscopy Facility, using ImageXpress 
Micro Widefield High Content Screening System, 20 ×  magnification, and 30 pictures taken per each well. 
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Data analysis was executed using MetaXpress Software Multi-Wavelength Translocation Application Module. 
Results are presented as the average of two experiments performed in triplicates.
MTT cytotoxicity assay
HEK cells were seeded onto a 96-well plate at a density of 1 × 104 cells per well and incubated at 37 °C with 
5 % CO
2
 overnight prior to the assay. Each compound was added in DMSO to reach final concentrations of 1 
µM, 5 µM, 10 µM, 20 µM and 50 µM, in triplicates, adjusting the final DMSO concentration to 0.5 %. After 24 h 
of incubation at 37 °C, 5 % CO
2
, 10 µL of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, 
10 mg/mL in PBS) were added to each well, and cells were incubated for another 2 h. Then, the medium was 
removed and the blue formazan crystals dissolved in 60 µL of acidified isopropanol. The plates were shaken 
to promote full dissolution of the crystals, after which the optical density (OD) at 570 nm (with a 690 nm ref-
erence filter) was measured using a microplate reader. Cell survival rates were calculated using equation (1), 
and the results presented as the average of two experiments performed in triplicates.
 
sample medium
cell control medium
Cell Survival  (%)  100
OD OD
OD OD
 
−
= × 
−    (1)
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